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DESIGN, PARAMETER OPTIMIZATION AND IN VITRO EVALUATION
OF IMPLANTABLE MEDICAL DEVICES
Yanfei Chen, PhD
University of Pittsburgh, 2018
The number of implantable medical devices ranging from dental implants to cardiovascular
implants has been exponentially increased in the last decades and various materials includ-
ing metallic materials and polymeric materials are used in medical device manufacturing. In
metallic materials, nitinol is widely used due to its superelasticity and well-known biocom-
patibility. Finite element modeling (FEM) along with in vitro and in vivo is being adopted
to evaluate the medical device performance in patients and optimize medical designs.
In this dissertation, four innovative implantable medical devices were developed and their
performances were evaluated using finite element modeling and in vitro testing: 1) ventricu-
loamniotic shunt for aqueductal stenosis treatment. It has the conduit to drain excessive
cerebrospinal fluid (CSF) to lower intracranial pressure in fetal brains and the anchors to
prevent the device dislocation during the treatment. The shunt tube design was optimized
using computational fluid dynamics calculations. The anchor design was determined with
ANSYS Static Structural and the prototype was manufactured based on modeling results.
In vitro pressure and flow rate measurement within shunt device demonstrate that the pres-
sure in fetal brain can be reduced by 95.2% while the pressure elevation in amniotic sac is
negligible. 2) TFN flow-diverter integrated with flow sensing system for cerebral aneurysm
post-treatment monitoring. The flexibility of TFN membrane was investigated using both
computational modeling and stretching experiment. As the TFN was wrapped on a flow-
diverter backbone with junction points, we evaluated the attachment patterns between a
TFN and stent backbone. Finally, micro-scale flow sensor was designed and fabricated
iv
based on the computational modeling. 3) compartmentalized stent to isolate the perfusion
of the abdominal organs. The fluid dynamics inside the arterial and venous organ perfusion
stent (OPS) was analyzed in terms of velocity distribution and wall shear stress (WSS).
In vitro pressure difference both in arterial and venous OPS showed that the stent deploy-
ment with perfusion flow to the abdominal organs will not generate a significant load on
the donor’s heart. 4) retrievable stent graft for noncompressible hemorrhage control. The
mechanical and biological properties of ePTFE membrane were investigated and the nitinol
framed backbone was evaluated in terms of radial force.
v
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1.0 INTRODUCTION
Medical devices and implants have attracted attentions in the last decades and the number
of medical devices are exponentially increased these years. According to the Implantable
Medical Devices market Analysis and Trends - Product, Material - Forecast to 2025, the
global implantable medical devices market is poised to grow at a compound annual growth
rate (CAGR) of around 5.4% over the next decade to reach approximately $54.28 billion
by 2025 [1]. Novel medical devices are also being developed with emerging techniques such
as 3D medical printing for customization and personalization [2] and nanofabrication for
ultra-thin and low-profile medical devices [3].
1.1 TYPES OF MEDICAL DEVICES
The medical devices can be categorized into dental implants, orthopedic implants, cardio-
vascular implants, breast implants, intraocular lens, orthobiologics and other implantable
products based on their applications.
1.1.1 Dental implants
Dental implants are inert, alloplastic materials for tooth loss management and lost oro-
facial structures replacement aid as a result of trauma, neoplasia and congenital defects.
Endosseous comprising a single and discrete implant unit in the forms of screw or cylinder
placed within dentoalveolar or basal bone is the most common dental implant. The most
common materials of dental implants are commercially pure titanium or titanium alloy. Al-
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ternative materials include ceramics such as aluminum oxide and other alloys such as gold
and nickel-chrome-vanadium [4].
1.1.2 Orthopedic implants
An orthopedic implant is to replace a missing joint or bone or to repair a damaged bone.
The most common types of orthopedic implants include pins, rods, screws and plates which
are used to anchor fractured bones during the healing process [5]. The implant strain needs
to be monitored regularly as indicators of potential fatigue failure as body movements and
body weights impose a dynamic load upon implanted orthopedic devices [6].
1.1.3 Cardiovascular implants
Cardiovascular devices are used to diagnose and treat heart diseases such as strokes and asso-
ciated health problems. Typical cardiovascular implants include aortic valve, cardiovascular
conduit, mitral valve, tricuspid valve, vascular graft, cardiovascular occluder and pulmonary
valve. The major complications associated with cardiovascular devices are infection and
thromboembolism [7].
1.1.4 Intraocular lens
Intraocular lenses are medical devices implanted inside the eye to replace the eye’s natural
lens when it is removed during he surgery. They are also used in the vision correction surgery
to restore a patient’s eyesight. The evaluation of the optical performance and aberrations
of the human eyes have been the research focus for many years and new advances in wave-
front technology have allowed measurements that can quantitatively describe the optical
performance [8].
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1.2 MATERIALS FOR MEDICAL DEVICES
There are specific requirements that medical implants must meet for long-term use in the
human body. Thus, a device must be properly “packaged” before installation in the hu-
man body. A wide of variety of polymers can be used in manufacturing biomedical im-
plants and packaging devices including Polyvinylidene Fluoride (PVDF), Polyethylene (PE),
Polypropylene (PP), Poly(methyl methacrylate) (PMMA), Silicones Parylene and PDMS,
Polyurethane (PU), Polytetrafluoroethylene (PTFE), Polyamide (PA), Polyimide, Liquid
Crystal Polymer (LCP) and Carbon Nanotube (CNT) Composites. The comparisons be-
tween these polymer materials can be found in [9].
Another category of widely used materials for medical devices are metallic materials
including stainless steel, magnesium, titanium and nickel-titanium. Metallic implants can
usually machine milled, cast and forged. These medical devices manufactured from metals
range from simple wires and screws to fracture fixation plates and total joint prostheses
(artificial joints) for hips, knees, shoulders, ankles, and so on. In addition to orthopedics,
metallic implants are used in maxillofacial surgery, cardiovascular surgery, and as dental
materials. Although many metals and alloys are used for medical device applications, the
most commonly employed are stainless steels, commercially pure titanium and titanium
alloys, and cobalt-base alloys [10].
Nickel-titanium, also known as nitinol, is a metal alloy of nickel and titanium in roughly
equal atomic percentages. Since the initial discovery of nitinol in 1963 [11], the shape mem-
ory properties of the nitinol have been widely applied in a wide range of medical devices,
specifically endovascular devices such as guidewires, stents, vena cava filters and arterial
septal defect closure devices [12, 13, 14, 15, 16]. All the important device characteristics
can be attributed to the specific properties of nitinol such as elastic deployment, thermal
deployment, kink resistance, constant stress, dynamic inference, stress hysteresis, temper-
ature dependence of stress, and other equally important properties of MRI compatibility,
biocompatibility and corrosion rate [17]. We discussed some key properties of nitinol in the
sections below.
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1.2.1 Shape memory and superelasticity
The shape memory response is defined as a mechanical deformation in a low temperature
state (i.e., martensite) with the deformations being fully recovered when the material is
heated to the transformation temperature (i.e., austenite). nitinol material properties can
be characterized by a specific stress-strain diagram different from conventional materials.
Figure 1 shows the schematic diagram of stainless steel, nitinol and living tissues. Stainless
steel has the elastic strain of below than 0.5% and shows plastic strain deformation once it
exceeds the elastic limit. In the plastic deformation region, the materials show a permanent
deformation and cannot be recovered after the stress is released. In the case of nitinol, the
deformation is also linearly proportional to the applied stress in the early stage. Thereafter,
the stress shows a plateau in the stress strain diagram and the strain is increased without a
significant increase in the stress. During the unloading, it also shows a plateau in the stress,
but with a different path in the diagram. Nitinol is recoverable up to 8% of deformation [18].
Living tissues such as bones also exhibit hysteresis in the loading-unloading cycles and this
similarity contributes to the biomechanical compatibility of nitinol in the medical implants.
An example of shape memory property in nitinol is self-expanding vascular stents. A
conventional vascular stainless steel with balloon expansion does not expand uniformly and a
rigid non-uniformly expanded stainless steel stent often causes significant arterial wall injury
as well as thrombosis formation. While the nitinol stents exhibit a more uniform expansion
and can prevent undesirable changes in stent position despite the vessel movements [20].
Therefore, lower vascular injury resulting from the mechanical action of nitinol stents on
the vessel wall is associated with a tremendous reduction in their thrombogenic potential
compared to stainless steel stents. Self-expanding nitinol stents are manufactured from a
diameter larger than that of the target vessel and the transformation temperature is typically
set to 30◦C. They can be easily collapsed below room temperature in a delivery system such
as catheters. The stent is often constrained by a retractable sheath or by other means in
order to prevent premature expanding during the delivery. At the target vessel site, the stent
is deployed from the delivery system and expands until it hits the vessel wall and conforms
to the shape of vessels. The stent now becomes superelastic at body temperature [21].
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Figure 1: Stress-strain diagram (schematic), for living tissues, NiTi superelastic alloy and
stainless steel (the left arrow indicates the elastic limit in stainless steel) [19].
1.2.2 Biocompatibility and surface treatment
The biocompatibility of nitinol material has been extensively investigated. An in vitro study
conducted by Ryha¨nen et.al concluded that nitinol has good compatibility with human os-
teoblasts and fibroblasts. Despite the higher initial nickel dissolution, which is the main cause
of allergic contact dermatitis, nitinol induced no toxic effects, decrease in cell proliferation,
or inhibition on the growth cells in contact with the metal surface [22].
The biological response to implant materials is directly related to their surface condi-
tions. Specifically, parameters such as chemical composition, crystallinity and heterogeneity,
roughness and wettability are all of great importance for biological response. Therefore, sur-
face treatment and modification can be used to improve the biological response to implant
materials.
5
Table 1: Surface treatments of the thin film nitinol
Symbol Treatment methods
Pretreatments
CT Cleaning: cleaning with acetone, methanol, and alcohol
PT1 Pretreatment 1: passivated in HNO3 for 40 min
PT2 Pretreatment 2: placed in BOE and passivated in HNO3 for 40 min
Surface treatments
UVTa Treated with UV for 15-60 min
TTb,c Treated thermally at 300-600
◦C in 10-40 min
HPTd,f,g Treated with 3%-30% H2O2 at 25-110
◦C for 0-15 h
Chun et al. proposed a superhydrophilic surface treatment in thin film nitinol (TFN) to
reduce thrombogenic behavior in thin film nitinol devices [23]. The thin film samples were
surface treated using one of the following three processes shown in Table 1. For each surface
treatment study, hydrophilicity was determined by measuring the wetting angles produced
by a water droplet on the film surface. Among the three processes, hydrogen peroxide
treatment (HPT) of 30% H2O2 solution at room temperature (25
◦C) for 15 h shows that
superhydrophilic response is not associated with an increased brittleness as well as a sufficient
titanium oxide layer on the film. In an in vitro platelet assay study, superhydrophilic treated
TFN (S-TFN) demonstrated neither platelet adhesion nor aggregation over time. An S-
TFN covered stent was placed in a 3.5 mm diameter left external iliac artery in a swine
model. S-TFN covered stent was observed to remain patent and rapidly endothelialized. This
neointimal growth suggests that the small amount of platelet adhesion on S-TFN contributes
to the healing process [24]. As thrombotic complications represent the key problems in the
management of vascular diseases, the TFN covered stent with a superhydrophilic surface
treatment may reduce the incidence in-stent thrombosis.
The main challenges regarding the materials in implantable medical devices are biocom-
patibility and device delivery. The biocompatibility issue always occurs at the interface
between implants and tissue or blood. The device materials should cause very little or no
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long-term damage to the artery and a long-term inflammation response from the surround-
ing tissues. As most of the medical devices are fabricated from rigid or ‘hard” materials,
the sharp edges and corners in the medical device might impose serious damages to the
relatively soft tissues during the surgical placement and implantation. In addition, these
implantable medical devices are quite bulky and could cause disturbance in the blood flow
or even significant coagulation or clot after being implanted in the blood vessels. As the new
trends of minimally invasive techniques in both vascular and orthopedic applications enable
the device to be delivered with a tiny puncture either in the blood vessel, tissue, or bones.
These techniques reduce the hospital stay of the patients, as well as reduce the risk and pain
from open invasive surgical procedures. While these techniques are a new trend and are
widely used for various implantable devices, rigid and bulky devices cannot be delivered via
these methods. Therefore, the ‘new generation” implantable medical devices should address
these issues with low-profile, and the use of soft and biocompatible materials.
1.3 FINITE ELEMENT MODELING
Finite element modeling (FEM) is a numerical method to solve the problems including struc-
tural analysis, heat transfer, fluid dynamics and electromagnetic fields, where the analytical
solution is typically intractable. FEM formulates the problems into finding the solutions in
a system of algebraic equations by dividing the domain of interest into discrete number of
elements. FEM is widely used in medical device design and parameter optimizations, among
which structural analysis is the most common area of interest for device mechanical char-
acteristics prediction. The governing equation for structure in static equilibrium is defined
by
[K] {u} = {F} (1.1)
where [K] is the stiffness matrix defined by the material properties, {u} is the nodal dis-
placement vector, and {F} is the associated load vector.
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FEM has been employed to investigate the mechanical properties of various stent designs
ranging from balloon expanding stents to nitinol self-expanding stents under different load-
ings such as crimping, deployment and bending in tortuous vessels. The physics in the stent
behaviors can be very complicated and FEM can be used to optimize the device design.
Larry et al. compared two different stent designs in terms of induced levels of stress in
the vascular wall. The coronary artery was modeled as an idealized vessel and represented
by a cylinder. Arterial tissue and stenotic plaque were modeled using a 5-parameter third-
order Mooney-Rivlin hyperelastic constitutive equation and the parameters were fitted by
the data from tension test of human femoral arterial tissue. Deformable-deformable contact
was used to describe the contact between the artery and the stent. It thereafter concludes
that an optimum stent design should retract sufficiently to prevent overstressing the vessel
wall but still maintain patency of the vessel and plaque scaffolding [25].
Wu et al. proposed an FEM to describe the expansion of a balloon expanding stent in
a curved vessel and the interactions between the stent and vessels. During the simulations,
conformity of the stent to the vessel, the minimum lumen area and the severest stenosis,
tissue prolapse between the struts and the stress in the tissues were calculated. As the blood
vessels are typically tortuous, stent bending is mainly attributed to tissue contact and link
deformation [26, 27].
Auricchio et al. evaluated the outcome of carotid artery stenting in the target vessel
model constructed from patient-specific images using finite element analysis [28]. The DI-
COM CTA images of a stenosed carotid bifurcation of a 83 years-old male patient were
processed to generate an STL file defining the lumen profile. Three self-expanding stent
designs with different configurations and sizes were evaluated and the stress induced to the
vessel wall as well as lumen gain and the vessel straightening were adopted as measures of
stenting impact on the vessel anatomy.
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1.4 DISSERTATION OUTLINE
Figure 2(a) shows the outline of medical device designing and manufacturing. The research
focus in this thesis dissertation is the design, modeling, parameter optimization and in vitro
testing of the developed medical devices. Figure 2(b) shows the types of medical devices
during my PhD researches and the red circled medical devices are the focus in this thesis
dissertation.
Figure 2: (a) Flow chart for medical device manufacturing process and red dashed box is
main focus in this dissertation. (b) Medical devices investigated in this dissertation and red
circled is the focus.
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2.0 VENTRICULOAMNIOTIC SHUNT TO TREAT FETAL
AQUEDUCTAL STENOSIS
2.1 INTRODUCTION
Children with an obvious pre-natal onset of hydrocephalus have been found to at high risk
for early death and multiple neurological complications [29]. According to the published re-
port, fetal hydrocephalus occurs at rate of 0.2-1 per 1,000 deliveries [30, 31, 32, 33]. AS is a
neurodevelopmental anomaly that causes pressure hydrocephalus and subsequent neurologi-
cal injury on developing neurons. Therefore, fetus with AS may benefit from decompression
of the ventricular system to prevent ongoing brain damage. In-utero shunting was first
attempted in the early 1980s as a means of improving pregnancy outcomes for fetal neu-
roanatomy, but later was abandoned due to a perceived lack of effect [34, 35], probably due
to the poor patient selection and technical difficulties. Shunts were placed in fetus with
lesions other than AS in the 1980s, leading to no clear benefit for shunting. Therefore,
a moratorium was placed on fetal ventriculoamniotic shunting [36] and there has been no
progress in treatment. Since there are no commercial available ventriculoamniotic shunts,
current management for fetal hydrocephalus caused by AS involves either pre-term delivery
followed by post-natal shunting or expectant management to term and then shunting. The
problems associated with these management options are that they will place mothers and
new-born babies at risks of disability or even death. In order to preserve the neurological
functions and allow for normal brain development while the pregnancy progresses to term,
a novel low-profile ventriculoamniotic shunt device needs to be developed for those fetuses
with AS.
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Emery et al. recently demonstrated the pre-natal detection for patient population with
AS for shunting using both ultrasound and MRI techniques [37]. In that case, the in-
utero ventriculoamniotic shunting can be performed on specific patient population to arrest
brain injury while allowing the pregnancy to proceed to term and after which, standard
ventriculoperitoneal shunting can be performed in the new-born period. The innovations of
the proposed ventriculoamniotic shunt include the following aspects: (1) It has the conduit
to drain excessive CSF to lower intracranial pressure in fetal brain; (2) The anchors can
prevent the device dislodgement during the treatment; (3) The one-way valve prevents the
reflux of CSF into the fetal brain to minimize potential complications.
2.2 METHODS
The schematic diagram of our proposed ventriculoamniotic shunt system implanted in a
fetal brain is illustrated in Figure 3. The catheter tube serves as the conduit to drain the
excessive CSF from the abnormal fetal brain to amniotic sac. Thermal shaped nitinol wires
are attached to the catheter tube using a Nylon suturing method as the anchors to prevent
device dislocation. The poly (ester urethane) ureas (PEUU) valve was partially fixed on the
distal end of the catheter tube to prevent the reflux of CSF. A detailed fabrication process
of the ventriculoamniotic shunt device is described in Section 2.4.1. The inset figure (in
rectangular box) in Figure 1 demonstrates the ON and OFF states of the one-way valve.
The PEUU valve remains closed (at OFF state) until the incoming CSF flow pushes it open
(at ON state). Thus, only the flow from fetal brain to amniotic sac is allowed.
2.2.1 Materials
2.2.1.1 Shunt tube materials Two different types of commercially available catheter
materials were used in prototyping. The 3 Fr and 4 Fr size tubes were obtained by mechan-
ical cut-trim process from Neuroform3 Microdelivery Stent System (Boston Scientific, MA)
and the Angiographic Catheter (SRD6913, Cordis, Johnson & Johnson Co., FL), respec-
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Figure 3: Schematic diagram of the proposed shunt system implanted in a fetal brain. The
inset figure demonstrates the OFF and ON state of the micro PEUU valve. The dimensions
of the shunt device are exaggerated as opposed to the fetal brain.
tively. These commercially available catheter materials are composites that contain multiple
polymer layers with the ultra-thin braided metal wires and are commonly used in either
neurovascular or coronary artery interventional. The catheter materials are one of the best
options for the prototype shunt because they have great kink resistance along with a certain
level of longitudinal flexibility, as well as biocompatibility.
2.2.1.2 Anchor materials Nitinol wires were used for fabricating anchors in ventricu-
loamniotic shunt prototypes. Nitinol is a common and well-known material widely used in
implantable biomedical devices because of its shape memory effect, superelasticity and bio-
compatibility. After the rediscovery of the shape memory effect in equiatomic Ni-Ti in 1962,
there has been an extensive research on this material. One of the most common reasons to
use nitinol in a medical device is to allow the efficient deployment in a less invasive procedure
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with its superelastic attribute. Most of the vascular disease treatment procedures require in-
struments and devices that can pass through very small openings and then elastically spring
back into the desired shapes. Nitinol clearly allows the greatest freedom in design compared
with other flexible materials [14]. The biocompatibility of the nitinol was also great. It has
been confirmed that almost no toxic effects or decrease in cell proliferation can be observed,
as well as there is no inhibiting effect on the growth of cells in contact with the metal surface
for clinical uses [22].
Various cold-drawn supelastic nitinol wires (Nitinol Devices & Components, Inc., CA)
were used for fabricating anchors. The elastic moduli of these wires are in the range of
41-75 GPa with the ultimate tensile strength of 1070MPa. The transformation temperature
(i.e., Austenite finish temperature) is in the range between -25 and 30oC. The composition
between Nickel and Titanium is 55.8 wt.% and 44.2 wt.%, respectively.
2.2.1.3 Valve materials Biodegradable polyurethane materials have been applied in
reconstruction of the cardiac valves and it showed satisfactory valvular functions [38]. PEUU
has been shown to possess good biocompatibility with non-toxic degradation products and
great elastomeric properties [39]. The PEUU was prepared by a two-step polymerization
process whereby polycaprolactone diol, 1,4-diisocyanatobutane, and 1,4-diaminobutane were
combined in a 1:2:1 molar ratio. In the first step, the pre-polymer was formed by reacting
polycaprolactone diol with1,4-diisocyanatobutane. In the second step, the pre-polymer was
reacted with 1,4-diaminobutane to extend the chain and to form the final polymer. The
PEUU coating and PEUU valve were fabricated by electrospinning [40]. Briefly, PEUU
was dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) at a concentration of 12% (w/v),
and electrospun either directly onto the superelastic nitinol mesh anchor to achieve a thin
layer of coating, or onto a rotating and translating stainless steel mandrel to yield a PEUU
membrane. The feeding rate of the PEUU solution through a charged capillary was kept at
1.5 ml/h. The collecting target (nitinol anchor or rotating mandrel) was located 10 cm from
the tip of the capillary. The voltage between the capillary and target was 19 kV.
13
2.2.2 In vitro assessment of both pressure and flow rates with the shunt devices
Figure 4 shows the test set-up for ventriculoamniotic shunt functionality assessment. The
syringe itself on the syringe pump (Model 100 Series, Cole-Parmer, IL) mimics the fetal
brain and the pump is used to mimic the pressure level increase in fetal brain. Either 3
Fr size of 4 Fr size device was connected to the test system to work as the shunt. The
balloon was attached on one end of the device mimicking the amniotic sac. Two micro
pressure sensors (Pendotech, NJ) were connected in the flow circuit to measure the pressure
levels both in the artificial fetal brain and amniotic sac, respectively. The pressure signals
were collected by a data acquisition system (NI USB-9162, National Instruments, TX) and
recorded in Labview (National Instrument, TX). The flow rates in the shunt were measured
by an accurate liquid flow sensor (SLI-2000, Sensirion, CA). We also connected a one-way
valve between the syringe pump and flow sensor to manually control the incoming flow to
the shunt to evaluate the shunt functionality by comparing the pressure levels without and
with shunt.
Figure 4: In vitro pressure and flow rate measurement set-up.
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It was reported that cerebrospinal fluid (CSF) has the similar viscosity as water [41],
so we used deionized (DI) water as the working fluid for the in vitro tests. First, the valve
was closed and the pressure levels were increased in artificial fetal brain with the pump flow
rate set as 50 mL/h. This experiment mimicked the gradual pressure elevation in fetal brain
induced by the CSF accumulation. Both the pressure levels in fetal brain and amniotic sac
were recorded after 7.2 s with total flow volume equal to 0.1 mL. This is marked as the
control group without shunt. Next the pressure levels were restored to the initial values.
Then, we turned on the valve and this process mimicked the shunting procedure. After all
the pressure levels were stabilized, we turned on the syringe with the same settings. Again,
this process mimicked the pressure elevation in fetal brain. And the corresponding pressure
levels and flow rates were measured and recorded. This is marked as the group with the
shunt.
2.2.3 Anchor functionality evaluation
The anchors functionality was evaluated by measuring the frictional force generated during
the shunt movement in the fetal skull and this frictional force served to prevent the shunt
dislocation. Figure 5 shows the top-view and front-view of the platform built on the isolation
table. A 5mm thick polydimethylsiloxane (PDMS) membrane was fixed on the optics mount
(Thorlabs, NJ), which acted as the simulating fetal skull due to their similar elastic modulus
[42, 43]. The PDMS membrane was punctured with a needle to create the incision. The
vertical translation stage with maximal travel distance 13 mm (Thorlabs, NJ) was used to
provide the shunt advancement through the artificial fetal skull layer and the corresponding
frictional force was measured by a load cell (LSB200, Futek, CA) mounted on the translation
stage.
2.2.4 One-way valve functionality evaluation
The ventriculoamniotic shunt device contains a low-profile one-way valve fabricated by PEUU
membrane. The functionality of this valve was qualitatively evaluated by visualizing the
fluid flow around the valve area. The whole device was immersed in the saline solution then
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Figure 5: Anchor resistance force measurement set-up; (a) top-view and (b) front-view of
the test system.
the red coloured food dye (Colorante rojo para alimentos, McCormick Culinary, MD) was
injected into the shunt. Both the valve motion and red dye flow in saline solution were
monitored under a high resolution digital camera (NEX-3, SONY, Japan) equipped with
stereomicroscopy (SZ61, Olympus, PA) at 4.5 times magnification.
2.3 ANALYSIS
2.3.1 Theoretical analysis and computational fluid dynamics (CFD) modelling
For an incompressible flow in the circular tube, the pressure drop can be calculated by
Darcy-Weisbach equation
∆P = fD · L
D
· ρv
2
2
(2.1)
where fD is Darcy friction factor, L and D is the length and diameter of the tube, ρ is
the fluid density and v is the mean flow velocity of the liquid. For the laminar flow, Darcy
friction factor fD is related to the Reynolds number (Re) by
fD =
64
Re
(2.2)
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Therefore, the volume flow rate Q can be calculated analytically and the result is given as
Q =
∆P · piD4
128µL
(2.3)
For the turbulent flow with Reynolds number greater than 4,000, Darcy friction factor fD is
given by:
1√
fD
= −2 log10
(
ε
3.7D
+
2.51
Re
√
fD
)
(2.4)
where ε is the roughness height. In this case, the volume flow rate Q needs to be calculated
numerically.
The fetal intracranial and intrauterine pressure was reported to be 30-35 mmHg and 5-9
mmHg, respectively [44, 45]. Therefore, the pressure difference between the fetal brain and
amniotic sac is estimated as 30 mmHg (4 kPa). Only the shunt tube was included in flow rate
calculation and a simplified cylinder model in CFD calculations was employed to optimize
the shunt design with maximal flow rate in the shunt when it was connected between the
fetal brain and amniotic sac. The 4 kPa pressure difference between the inlet and outlet was
maintained in the cylindrical tube (shunt) and the fluid in the tube has the density ρ =1000
kg m−3 and viscosity µ = 1.003 × 10−4 Pa s−1 [46]. A laminar flow model was assumed
for 3 Fr catheters and turbulent flow model for 4 Fr catheters. Then we were able to solve
for the inlet velocity as well as flow rate for different length (from 3 cm to 10 cm with a 1
cm increment) and diameters (ID = 0.69 mm for 3 Fr catheter and ID = 0.94 mm for 4 Fr
catheter).
2.3.2 Anchor resistance analysis
Nitinol wires with different pre-shaped structures will be attached on the outer surface of
the catheter as an anchor to prevent the device dislocation by generating a sufficiently high
frictional force. We assume that the frictional force is proportional to the support force
when the anchor was compressed during the device movement through the skulls incision, so
we can analyse the maximal compression force in the shunt movement. A line model with
circular cross-section (diameter of the cross-section d = 0.10 mm) was employed in ANSYS
Static Structural 15.0 (ANSYS Inc., Canonsburg, PA) (shown in Figure 6). The length of the
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anchor L (mm) and the height H (mm) will be varied to evaluate the maximum compression
force. Two vortices at two ends are assumed to be fixed and a downward displacement
loading with the magnitude equal to H was applied in the middle section of the anchor. The
material property of the nitinol is defined as Youngs Modulus E = 60 GPa and Poissons ratio
ν =0.3. Then we are able to evaluate the compression force associated with the displacement.
Figure 6: Simplified model to analyse anchor resistance in finite element modelling.
2.4 RESULTS AND DISCUSSIONS
2.4.1 Prototype devices
Figure 7 shows the first prototype shunt device with nitinol braided anchor. First, the com-
mercially available catheter material (3 Fr catheter) was obtained by a precision mechanical
cutting process in the required length as the shunt tube. Both ends were smoothed by
eliminating any metal wires and burrs in composite structure with mechanical polishing and
micro laser melting. Then, the ultra-thin nitinol wires (0.004-0.005” diameter) were inte-
grated with the shunt tube using both biocompatible polymer adhesives and 7-11 size Nylon
suturing materials as the anchor. The device can be easily collapsed into a PTFE tube
with inner diameter 2 mm. The nitinol mesh will be released after compression due to the
material superelasticity and it will prevent the device dislocation by deformation. Then all
the anchor regions were covered with PEUU membrane with electrospun coating to prevent
any leakage of the fluid flow.
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Several prototype devices were designed and manufactured by integrating with three
different anchor geometries, as shown in Figure 7. Anchor geometries were created with the
ultra-thin nitinol wires (0.004-0.005”) by thermal shape setting technique. Then, the anchors
were attached on the middle of the shunt tube by mechanical clamping. As described earlier,
both biocompatible polymer adhesives and 7-11 size Nylon suturing materials were used for
the attachment. Figures 7(a-c) show the prototype devices with coiled spring anchors, two
bumper anchors and two tilted elastic anchors, respectively. Finally, the PEUU membrane
was partially attached on one end of the shunt tube using the micro-suturing methods with
the size of 10-11 sutures (Figure 7(d)). This attached PEUU membrane functioned as the
passive one-way valve of the ventriculoamniotic shunt device.
Figure 7: Prototype ventriculoamniotic shunt with anchors and one-way valve.
Figure 8 shows the deployment of the device in vitro. All three types of anchors can be
easily collapsed and inserted into the 4 Fr size shunt tubes and successfully deployed with a
10 Ga needle simply by pushing the device using a push rod (Figures 8(a-d)). No significant
damages or luminal side deformation were observed (Figure 8(d)). In the next section, we
show the performance of the anchors by deforming upon compression to demonstrate the
prevention of the device dislocation.
A new set of prototype device was also developed as shown in Figure 9(c) and (d). The
new developed shunt device consists of two components, a cage at one end of the shunt tube
to prevent tube occlusions and an anchor to prevent the device dislocation during the surgical
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Figure 8: Captured images of the device deployment in a 10 Ga needle.
treatment. Both the cage and anchor were fabricated from nitinol wires (0.0090” diameter,
NDC Inc., Fremont, CA, USA) and wrapped onto two types of aluminum rod (Figure 9(a).
Stainless steel wires (Malin Co., Brook Park, Ohio, USA) were used to fix the nitinol wires
on the lathed aluminum rod (Figure 9(b)). Then the whole parts were placed in furnace
(Lindberg/Blue Moldatherm Box Furnaces, Fisher Scientific, Pittsburgh, PA, USA) with
temperature set as 500◦ for 20 minutes. The nitinol wires were thermally set to the desired
shapes as cages and anchors. Finally, the thermally shaped cage and anchor were attached
on a 3 Fr catheter using the USP 6-0 Nylon sutures (Aros Surgical Instruments Corporation,
Newport Beach, CA, USA) and biocompatible adhesive (Henkel, Stamford, CT, USA).
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Figure 9: (a) Aluminum rods used for thermal shaping. (b) Wrapped nitinol wires on an
aluminum rod for anchor fabrication. (c)-(d) Manufactured prototype shunt device with
cages and anchors.
2.4.2 In vitro evaluation on pressure level and flow rate changes
2.4.2.1 Computational fluid dynamics (CFD) calculations Figure 10 shows the
calculated flow rates with respect to different length (from 3 cm to 10 cm with a 1 cm
increment) and diameters (ID = 0.69 mm for 3 Fr catheter and ID = 0.94 mm for 4 Fr
catheter) of shunt tubes using both theoretical equations described above and CFD modeling.
These results demonstrate that the flow rate increased with diameter and decreased with
length of the shunt tube. Specifically, flow rate in a 4 Fr shunt decreased from ∼1200 µL·s−1
to ∼600 µL·s−1 when the shunt length was increased from 3 cm to 10 cm, while the flow rate
in 3 Fr shunt decreased from ∼450 µL·s−1 to ∼200 µL·s−1. Also, 4 Fr shunt shows a larger
flow rate compared with 3 Fr shunt with the same length. The theoretical analysis results
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also show the similar trends and CFD modeling results match quite well with it. Therefore,
we can conclude that a catheter with a larger inner diameter and smaller length will be
preferred as the candidate for shunt to drain maximal amount of CSF flows.
Figure 10: Calculated flow rate within device with respect to length and diameter of shunt
tubes using theoretical equations and CFD modeling.
A shorter shunt will be challenging to be placed in the fetal skull, so longer shunts will
be preferred in order to minimize the surgical difficulties in practice. Also a larger diameter
of catheter will need a larger insertion needle, which means higher risks to the mother of
premature labor, amniotic fluid leak, uterine trauma or placental separation and fetal brain
trauma [47], so the 5Fr or larger catheters were not excluded in the shunt candidates. Taking
these factors into account, a 7 cm long 4Fr catheter was finally chosen as the shunt candidate.
2.4.2.2 Pressure and flow rate measurement Figure 11 shows the measured pressure
levels and flow rates with a 3Fr catheter (7 cm long) as the ventriculoamniotic shunt. The
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initial pressure in the fetal brain was set as 0.86 psi and in the amniotic sac it was 0.24 psi.
Therefore, the pressure difference between the two was 0.64 psi (32 mmHg). Figure 11(a)
shows the pressure levels in the fetal brain with the valve closed, i.e. the control group. The
pressure in the fetal brain ramped to as high as 4.2 psi with the syringe pump running for
7.2 s if the shunt was not connected in the system. The pressure elevation in fetal brain is
388% and this high pressure represented the high risk of fetal brain damage. Figure 11(b)
shows the pressure levels in the fetal brain and amniotic sac with the valve open, i.e. the
shunt was connected and functioning. We can see that the pressure level in fetal brain first
dropped to ∼ 0.15 psi and the pressure level in amniotic sac slightly increased to ∼ 0.25
psi once we turned on the valve. The pressure redistribution occurred between the fetal
brain and amniotic sac and the excess CSF drained from the brain to the amniotic sac.
The corresponding flow rate in the shunt during this process was measured and represented
by the peak value in Figure 11(c), which is 2237.2 µL min−1. After all the pressure levels
became stable, the pressure level in fetal brain only rose to ∼ 0.48 psi with the syringe pump
running for 7.2 s. There was also a slight increase in the pressure level from 0.24 psi to 0.30
psi in the amniotic sac, as shown in Figure 11(b). Therefore, the pressure decrease in fetal
brain is 88.6% (from 4.2 psi to 0.48 psi) while the pressure elevation in the amniotic sac is
25%.
Figure 12 shows the measured pressure level and flow rate with 4 Fr catheter (7 cm) as
the ventriculoamniotic shunt. The initial pressure levels in fetal brain and amniotic sac were
still set as 0.86 psi and 0.24 psi, respectively. Figure 12(a) shows that the pressure in fetal
brain dropped suddenly to ∼ 0.15 psi after turning on the valve. The corresponding flow rate
in the shunt during this process was represented by the peak value in Figure 12(b), which is
4134.6 µL min−1. This flow rate is larger than the one in the 3 Fr case. Then, the pressure
level in fetal brain slowly increased to ∼ 0.2 psi with the syringe pump running for 7.2 s.
There was also a slight increase in the pressure level from 0.24 psi to 0.29 psi. Therefore, the
pressure decrease in fetal brain is 95.2% (from 4.2 psi to 0.2 psi) and the pressure elevation
in the amniotic sac is 20.8%.
The pressure measurement demonstrates that the ventriculoamniotic shunt relieved the
high pressure in the fetal brain with draining the excess amount of CSF to the amniotic sac.
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Figure 11: (a) Pressure levels in the simulated fetal brain and amniotic sac in control group;
(b) Pressure levels in the simulated fetal brain and amniotic sac with 3 Fr catheter shunt
device; (c) Flow rate in the 3 Fr shunt device.
Further pressure increase in fetal brain will also be relieved after inserting the shunt. We
can see that 4 Fr shunt shows superior performance on CSF draining and pressure relieving.
This result matches well with our theoretical analysis. The measured peak flow rates for 3 Fr
and 4 Fr shunt are much lower than the CFD calculations, mostly because we did not take
the length of silicone tube in the experiment as well as frictional loss in the tube connections
into account in our calculations. Considering all the factors, the 4 Fr catheter proves to be a
good candidate for the ventriculoamniotic shunt. It can relieve 95.2% of the abnormal high
pressure in foetal brain while only increasing the amniotic sac pressure by 20.8%. The actual
amniotic sac size is much larger than the fetal brain, so the impact on the amniotic sac will
be negligible.
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Figure 12: (a) Pressure levels in the simulated fetal brain and amniotic sac in control group;
(b) Pressure levels in the simulated fetal brain and amniotic sac with 4 Fr catheter shunt
device; (c) Flow rate in the shunt device.
2.4.3 Anchor functionality
2.4.3.1 Finite element (FE) analysis of anchors In order to evaluate the effect of
anchor height and length on the compression force, we varied the anchor height from 1 mm
to 4 mm with fixed length L= 8 mm and the result is shown in Figure 13(a). An asymptotic
function was fit to the results in Origin 2015 (OriginLab, Northampton, MA) and the data
reveals that increasing the anchor height will elevate the generated compression force, but
the improvement is not significant after the height is beyond 4 mm. We also varied the
anchor length from 10 mm to 30 mm with fixed height H =1 mm and the result is shown in
Figure 13(b). An exponential function was fit, which shows that decreasing the anchor length
will increase the generated compression force significantly. Therefore, we may conclude that
an anchor design with larger height and lower length provides the optimal frictional force
during the movement. However, considering the manufacturing difficulty and performance
improvement, a height between 3-4 mm and length between 5-10 mm were considered as the
design parameters.
This FE analysis only applies to the two bumper anchor structure (Figure 7(b)), while the
behaviors for coiled spring and tilted curves are more complicated since other deformations
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such as twisting will be involved when the anchor part moves through the PDMS membrane.
Therefore, more complicated boundary conditions need to be considered for the FE analysis
in more realistic situations.
Figure 13: Calculated compression force by anchor with respect to length and height in finite
element analysis.
2.4.3.2 Force measurement of the anchors Three prototype shunts with different
anchor designs were evaluated for anchor functionality. If the shunt anchor is effective in
preventing the dislocation, then it will generate higher frictional force during the shunt
movement in the PDMS membrane. According to this assumption, we measured the force in
three prototype shunts with different anchor designs shown in Figure 7. In order to evaluate
the effectiveness of several anchor designs, we compared the measured frictional forces in
different prototype anchors. Although PDMS may not provide the same surface condition as
the one of fetal skull in terms of frictional coefficients, it does not influence our comparison
results on anchors.
Figure 14(a) shows the the measured force for prototype with coiled anchors (Figure
7(a)). The black line represents the corresponding frictional force when only the bare shunt
(no anchor) region was pushed through the PDMS membrane and the averaged force is 0.18
N. The red line represents the corresponding frictional force when the anchor region was
pushed through the PDMS membrane and the averaged force is 0.27 N. It shows that the
presence of anchor provided 0.1 N frictional force to prevent the shunt dislocation during the
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surgery operation. Figure 14(b) shows the measured force for prototype with two bumpers
(Figure 7(b)). The shunt anchor region first went through the PDMS membrane and the
averaged frictional force is 0.15 N (left on the red dashed line). Once the no-anchor region
was pushed through the PDMS membrane, the frictional force abruptly ramped to 0.20 N
(right on the red dashed line). The frictional force on the anchor region is lower than the
no anchor region, possibly due to the smoother nitinol anchor region compared to the bare
catheter. Therefore, the anchor shows no effects to prevent the shunt dislocation. Figure
14(c) shows the measured force for prototype with two tilted curves (Figure 7(c)). The
movement pattern is similar. First the shunt anchor region was pushed through the PDMS
membrane and the frictional force generated by the anchor is up to 1.0 N (left on the red
dashed line). After the anchor passed the PDMS membrane, the frictional force ramped
down to 0.2 N (right on the red dashed line). Therefore, a prototype anchor with tilted
curves provided an additional ∼0.80 N frictional force to prevent the shunt dislocation.
2.4.3.3 One-way valve functionality The one-way passive used in the ventriculoam-
niotic shunt was adopted from the geometry of bi-leaflet valve [48]. Figure 15 shows the
finite element modelling results of the simplified one-way valve in ANSYS Workbench Static
Structural 15.0. The Youngs Modulus for valve material is 3 MPa with Poissons ratio 0.49
and Youngs Modulus is 1 GPa with Poissons ratio 0.46 for catheter material. Figure 15(a)
shows that the poly(ester urethane) urea (PEUU) valve is deformed outward and pushed
open with the forward flow. Figure 15(b) shows that the PEUU valve is deformed inward
and remains closed with the reversed flow. Therefore, it proves the functionality of the
passive one-way valve in allowing the forward flow while resisting the reversed flow.
Figure 16 shows the in vitro testing result of the one-way valve with flow visualisation.
Figures 16(a-c) show that the injected red dye into the shunt tube created high pressure
and forwarded the flow to push the PEUU membrane valve open. Therefore, the red dye
diffused into the clear DI water in all directions through the gap between the valve and end
of the tube. Due to the elasticity of the PEUU membrane, the valve restored to its original
position (Figure 16(d)) when the red dye flow in the shunt stopped. There was no flow
observed around the shunt when the valve was closed. This flow visualisation is a qualitative
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Figure 14: Anchor force measurement results. (a) Frictional force on the anchor region and
bare shunt region for coiled spring anchor structure. (b) Frictional force on the anchor region
and no anchor region for two bumpers anchor structure. (c) Frictional force on the anchor
region and no anchor region for two tilted curves anchor structure.
way to show the proof-of-concept of the valve testing that confirmed the functionality of
the one-way valve for controlling the flow in the shunt device. And the experimental and
modeling results agreed with each other.
2.5 CONCLUSIONS
In this study, we proposed an improved shunt design to readdress the concept of ventricu-
loamniotic shunting for fetal isolated aqueductal stenosis. The low-profile prototype ventricu-
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Figure 15: Finite element modelling of the one-way valve in ANSYS Workbench 15.0. (a)
The valve is open with forward flow. (b) The valve is closed with reversed flow.
Figure 16: Flow visualization of the one-way valve functionality using food dye.
loamniotic shunt integrated with dislodgement prevention anchors and the passive one-way
valve was designed and manufactured. Both 3 Fr and 4 Fr catheters served as the shunt tube
and thermal shaped nitinol wires were attached on the outer tube surface to form the an-
chors. Finally, the PEUU membrane was attached on one end of the shunt tube as a passive
one-way valve. In vitro pressure level and flow rate measurement proved the shunt function-
ality as the 3 Fr shunt relieved 88.3% while the 4 Fr shunt relieved 95.2% of the abnormal
high pressure in fetal brain. The measurement of frictional force generated by anchors upon
compression through the simulated fetal skulls compared the anchor performance of three
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different designs quantitatively. The flow visualization of passive one-way valve functionality
was evaluated with flow visualization. In summary, our new ventriculoamniotic shunt pro-
totype showed superior performance of draining the excess cerebrospinal fluid from the high
pressurized fetal skull, reducing the likelihood of device dislodgement during the surgery op-
eration and preventing the reflux of amniotic fluid into the cerebral ventricles. Future work
will include the in vivo functionality studies and the biocompatibility testing of the device
using sheep models. And the one-way valve will be optimized to prevent thre reflux of CSF.
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3.0 TFN FLOW-DIVERTER INTEGRATED WITH SENSING SYSTEM
FOR CEREBRAL ANEURYSM TREATMENT
3.1 INTRODUCTION
Cerebral aneurysm is a cerebrovascular disorder caused by the local ballooning in the blood
vessels that allows blood to flow into a sac outside of its normal flow path. The reported
prevalence of unruptured cerebral aneurysm varies from 3.6% to 6% in the population [49]
and the aneurysm represents the potential for a rupture or leak which results in hemorrhagic
stroke, permanent nerve damage or death. Effective monitoring and early treatment is
therefore critical to prevent further arising complications. Current treatments of cerebral
aneurysm involve surgical procedure and endovascular embolization. Due to the high risk
of morbidity associated with clipping [50], coiling has been adopted as a common procedure
and the risks were reduced by 7.4% [51]. While coiling is less invasive, the cure rates still
lag behind those of clipping, due to persistent blood flow into the aneurysm in up to 38% of
patients [52].
A more recent and compelling treatment technique is the use of a flow diverter deployed
inside the vessels adjacent to the aneurysm. A flow diverter effectively reduces blood flow
into the aneurysm and a complete occlusion rate of 76% has been seen in the clinical outcome
[53]. Complete occlusion of the aneurysm after treatment significantly reduces the risk of a
rupture compared to partial occlusion and it has shown risk of re-rupture to be 1.1% [54] in
the cases of a ruptured aneurysm.
A neurovascular catheter is typically used to deliver a flow diverter to the cerebral
aneurysm site. However, it presents a challenge in that it can cause the flow diverter’s
metal film to undergo extreme radial deformation and extreme bending as it navigates the
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highly tortuous vessels. In this case, the microflow sensor should be flexible and stretchable
to accommodate utilization in the cerebral blood vessels.
High-quality catheter angiography is generally employed to evaluate subarachnoid hem-
orrhage for unruptured aneurysms. But angiography examination is qualitative and fails to
disclose an aneurysm in 10 to 20 percent of cases of subarachnoid hemorrhage [50]. Another
approach to monitor the aneurysm is pressure sensing. Both the direct intra-aneurysmal
sac pressure measurement using tip-pressure sensors and wireless pressure sensing for en-
dovascular aneurysm repair has been reported [55, 56, 57]. However, these sensors are not
sufficiently flexible for use in intracranial endovascular procedures, which typically require
a 1.7 Fr micro-delivery catheter (i.e., OD=0.56 mm). Also the recent studies have con-
firmed that the intra-aneurysm pressure is not significantly changed after the coil placement
[58, 59, 60, 61, 62], which means the pressure sensor is not suitable for monitoring intra-
aneurysm hemodynamic quiescence. Therefore, a flow sensing system needs to be developed
and can be integrated with the TFN flow-diverter for cerebral aneurysm treatment monitor-
ing.
In this work, we demonstrated the microfabricated thin film nitinol (TFN) as the porous
mesh in the flow diverter can be stretched up to 500% and deformed up to 180◦ in bending
without mechanical failures, suggesting the safe deployment of TFN covered flow diverter
in a neurovascular aneurysm. The proposed stretchable microflow sensor package can be
conformally integrated with a TFN covered stent to monitor the cerebral aneurysm hemo-
dynamics quantitatively inside the blood vessels. Therefore, the efficacy and progress of the
aneurysm treatment process can be evaluated by measuring the incoming flow rate into the
aneurysm sac.
3.2 METHODS
The proposed TFN flow-diverter integrated with the flow sensing system consist of three
components: nitinol backbone frame, micropatterned TFN as the stent graft and a micro-
scale wireless flow sensing system. In the methods section, we described the methods for
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analyzing the fluid patterns inside the cerebral aneurysm, TFN flexibility and stretchability,
microflow sensor flexibility and the functionality of the proposed smart TFN flow-diverters
for cerebral aneurysm treatment and monitoring.
3.2.1 Computational modeling
3.2.1.1 TFN flexibility evaluation The desired micropatterned TFN needs to with-
stand large deformation along with the nitinol backbone frame, therefore, we need to evaluate
the flexibility of the TFN as the covering membrane for flow-diverter device. 3D compu-
tational study employs a simplified geometric model of a microstructured TFN membrane.
The finite element modeling estimated the mechanical behavior of the structure upon uniax-
ial stretching in radial and longitudinal directions, biaxial stretching and bending. ANSYS
Structural Analysis 15.0 was utilized with user-defined material properties for the TFN mem-
brane to calculate the stress and strain fields. To reduce the computational complexity, only
a small fraction of the TFN membrane structure (6 repeated patterns) was modeled.
For radial loading, the TFN structure was modeled with purely Hex20 elements (Figure
17(A)) and two symmetric displacement loadings in radial direction were applied on two
edges of the structure (Figure 17 (B)). The structure surface was constrained from out-
of-plane motion to simplify the problem into 2 dimensional motion. The magnitude of
the displacement loadings was gradually increased and the maximal equivalent stress as
well as maximum principle strain fields were calculated to determine the potential fracture
locations in the structure. Here, we defined the strain % as the displacement loading over
the original distance and assumed that the fracture occurred on the location where the
maximum principle strain exceeded the strain limit of the nitinol material (Figure 17 (C)).
The calculation iterations were also shown in Figure 17(D).
The TFN structure was modeled with a combination of Hex20 and Wed15 elements
in longitudinal (axial) loading analysis (Figure 18). Similarly, two symmetric displacement
loadings in axial direction were applied on two edges to stretch the TFN membrane out in
horizontal direction. We gradually increased the magnitude of the displacement loading and
the maximal equivalent stress as well as maximum principle strain field was computed.
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Figure 17: (A) The meshed model for TFN membrane in ANSYS Static Structural 15.0.
(B) The boundary conditions in the modeling analysis. Red arrows represent the symmetric
displacement loading directions (radial direction). (C) The relationship between the calcu-
lated maximum principle strain % (in y axis) and the applied strain % (in x axis). (D) The
force convergence plot with Newton-Raphson method.
Figure 19 describes the details for modeling of the biaxial stretching. In first step, a
100% strain displacement was applied on two faces on the top and other two on the bot-
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Figure 18: (A) The meshed model for TFN membrane in ANSYS Static Structural 15.0.
(B) The boundary conditions in the modeling analysis. Red arrows represent the symmet-
ric displacement loading directions (axial direction). (C) The force convergence plot with
Newton-Raphson method. (D) The relationship between the calculated maximum principle
strain % (in y axis) and the applied strain % (in x axis).
tom. This is the step where the TFN structure was stretched in the radial direction before
being wrapped around a stent backbone. We only applied 100% strain displacement to min-
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imize the buckling issues, which will increase the computation complexity [63]. This biaxial
stretching experiment was to demonstrate the effects of radial strecthing on longitudinal
stretching.
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Figure 19: (A) The meshed model for TFN membrane in ANSYS Static Structural 15.0. (B)
The boundary conditions in the modeling analysis. Blue arrows represent the displacement
loading directions (radial) in the initial step and red arrows represent the displacement
loading directions (axial) in the subsequent step. (C) The relationship between the calculated
maximum principle strain % (in y axis) and the applied axial strain % (in x axis). (D) The
force convergence plot with Newton-Raphson method.
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Figure 20 presents the modeling results of the mechanical bending. To analyze the
mechanical behaviors of the TFN structure subject to deployment in curved vessels, a three-
point bending analysis was performed with a combination of Hex20 and Wed15 elements.
As the TFN membrane will be attached on the nitinol backbone using biocompatible
glues. It is important to evaluate the glue patterns between the microporous TFN mem-
brane and relatively rigid backbone. Figure 21 shows the details for the finite element
calculation. We modeled 24 repeated patterns for TFN membrane and defined some glue
positions between the TFN and stent backbone.
3.2.1.2 Sensor functionality analysis We integrated a flow sensor with the flow-
diverter to monitor the hemodynamics within the cerebral aneurysm. The proposed flow
sensing system is capable of detecting the incoming flow rate. The idea of a flow sensor is
to adopt the parallel plate capacitor structure, i.e., a thin dielectric elastomer layer sand-
whiched between two metallic layers. The sensor capacitance change corresponds to the
dielectric elastomer layer deformation in the flow environment to monitor fluid dynamics.
For a rectangular layer of an incompressible, homogeneous elastomer that is bonded with
rigid plates on both sides shown in Figure 22(a), the relationship between applied pressure
P on two electrode plates and the resultant strain e can be described by [64]
P =
EC
2
(S2 − S20)− E
[
1 +
1
3
(
B2 − L2
B2 + L2
)2]
log(1− e) (3.1)
where E is the Young’s modulus of the elastomer, 2L and 2B are the length and width of
the rectangular layer, respectively, C is a constant defined by
C =
4
3
+
B
L
(
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)
(3.2)
S is a geometric parameter known as shape factor and is defined by
S =
BL
2(L+B)t
=
S0
1− e (3.3)
where 2t is the resultant thickness of the layer upon compression and S0 is the original shape
factor with initial thickness 2T before compression. The strain can be calculated by
e =
2T − 2t
2T
=
∆T
T
(3.4)
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Figure 20: (A) The meshed model for TFN membrane in ANSYS Static Structural 15.0. (B)
The boundary conditions in the modeling analysis. The blue rollers in the top view represent
the unconstrained motion along the long axis direction. The red arrows in the front view
represent the applied force direction and the blue triangles represent the constrained motion
along the force direction. (C) The relationship between the calculated maximum principle
strain % (in y axis) and the applied bending force (in x axis). (D) The force convergence
plot with Newton-Raphson method.
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Figure 21: (A) The meshed model for TFN membrane in ANSYS Static Structural 15.0.
(B) The quality of the meshed element and the value close to 1 represents high quality while
the value close to 0 represents poor quality. The overall element quality is lower due to the
addition of the glue junction points. (C) The plot of force convergence with Newton-Raphson
method.
The dynamic pressure P generated by the liquid flow in a tube is defined as
P =
1
2
ρv2 (3.5)
where ρ is the density of the liquid and v is the fluid velocity.
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Figure 22: Concept of capacitive flow sensor. (a) Compression with applied pressure P; (b)
Parallel plate capacitor model.
The theoretical equation to calculate capacitance of a parallel plate capacitor model
(Figure 22(b))is given by
C =
εrε0A
d
(3.6)
where ε0 is the permittivity of free space (8.85 × 10−12 F/m), εr is the relative dielectric
constant of elastomer, A is the area of the electrode plate and d is the distance between
these two plates, i.e., the thickness of the elastomer. Therefore, the flow velocity in the fluid
environment is related to the capacitance change in the capacitive flow sensor by resultant
strain upon dynamic pressure. The capacitance change can be determined by
∆C = C − C0 = ε0εr(4BL∆T )
Tt
≈ C0e ∝ ∆T
T 2
(3.7)
Here, we assumed that ∆T << T and ∆B,∆L ≈ 0 for simplicity. Thus the capacitance
change can be assumed to be proportional to the elastomer thickness change over the square
of the original thickness. Equation (3.7) can be used to calculate the sensor sensitivity in
terms of capacitance change. This calculation provides the guideline for the capacitive flow
sensor design in the later sections.
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3.2.1.3 Computational fluid dynamics (CFD) modeling of the aneurysm In or-
der to determine the designed flow sensor locations within the cerebral aneurysm to maximize
the input signals (i.e., flow rate), we assess the flow patterns in the aneurysm. A simplified
aneurysm model with parent vessel was developed to calculate the flow velocity and pressure
distributions with defined boundary conditions including inlet velocity and outlet pressure.
Here, we simplified the saccular cerebral aneurysm into an ideal model in order to reduce
the computational complexity. Another type of cerebral aneurysm (i.e., fusiform) was not
considered.
3.2.1.4 Flow sensor mechanics analysis Flexibility of the flow sensor is also a critical
criteria as it will be integrated with the flow-diverter and the undergo large deformations
such as collapse and deployment to the target site and navigation through the highly tortuous
vessels in the brain. To study the mechanical behavior of the designed structures, we used
finite element analysis (ABAQUS CAE 2016, Dassault Systems, USA) for radial stretching
and bending (Figure 23). In the radial stretching, a deformable cylindrical surface was added
in the model as an expander and then meshed with SFM3D4R elements (4-node quadrilat-
eral surface element with reduced integration). In order to ensure the wrapped sensor was
stretched radially along with the uniform expansion of the expander, the contact between
the expander and sensor pattern was modeled as frictionless in the tangential direction and
hard contact in the normal direction. The applied strains to the sensor was up to 500%,
which was increased incrementally over time. For the bending model, a deformable cylinder
was added and aligned with the sensor coaxially. It was meshed with C3D8R elements.
A tie constraint was applied on the contact surface between outer base support and inner
sensor surface to ensure. A pair of rigid cylindrical surface was added to the top and base
support, then an upward displacement was applied to increase the bending angle from 0 to
180 degrees in the base. All the rigid cylindrical surfaces were meshed with R3D4 elements
(4-node 3-D bilinear rigid quadrilateral). The contact between the rigid support faces and
the base support surface was modeled as frictionless in the tangential direction and hard
contact in the normal direction.
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Figure 23: FEA geometric model. (a) Base setup for radial stretching simulation in which
the sensor pattern (two unit cells in axial length) is wrapped circumferentially around an
expandable cylinder. (b) Base setup for radial bending in which the sensor (6 unit cells in
axial length) is fixed to a supporting base cylinder which undergoes bending up to 180o by
displacing the bottom rigid cylinder upwards against the two top rigid cylinders.
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3.2.2 Experimental setup for TFN flexibility evaluations
3.2.2.1 Uniaxial stretching A small rectangular sample of TFN was cut and affixed
to a custom-made mechanical stretcher [63, 65]. Two separate uniaxial loading tests were
performed; one in the radial direction, and one in the longitudinal direction. For the radial
loading, the sample was aligned vertically along the length of the stretching machine such
that strain was only applied widthwise along the diamond fenestrations. For the longitudinal
loading, the sample was aligned horizontally along the length of the stretching machine
such that the strain was only applied lengthwise along the diamond fenestrations. The
stretching machine had one fixed support block (slide) with a copper strip running down its
length, the sample was glued to the copper and colloidal silver paste was applied to secure
electrical conductance. The other side of the sample was affixed to an adjustable support
block (slide) in the same fashion. The copper strips were connected to wires so that the
electrical resistance of the sample could be measured via a digital multimeter (Model 2100,
Keithley, Cleveland, OH). An initial resistance measurement was taken while the sample
was at rest (0% strain) for a baseline. Resistance of the sample was recorded to document
the structural integrity of the material whereas an increase of resistance would indicate
structural degradation of the sample. The adjustable slide was then moved in approximately
2% increments to increase the distance between the two slides, thereby increasing the strain
on the sample. The percentage of the strain was calculated by the percentage increase of
distance over the original distance. The increase in resistance compared to the increase
in strain was recorded and plotted for each increment until the mechanical failure of the
sample. After the first fracture point on the sample occurred, the structure was investigated
by scanning electron microscopy.
3.2.2.2 Biaxial stretching The samples were first placed under preloaded strains rang-
ing from 300% to 360% along the width (in the radial direction) and then connected to
two separate electrical wires. The samples were wrapped circumferentially around the wires
to mimic the shape of the stent backbone. Similarly to the uniaxial sample, it was glued
at every point around the wire and electrical conductivity was ensured using colloidal silver
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paste. One wire was attached to the fixed slide, and the other attached to the adjustable
slide. The testing then proceeded the same way as for the uniaxial sample.
3.3 RESULTS
In this section, we present the mechanics evaluation of the microstructured TFN, determina-
tion of the glue locations on a TFN flow-diverter, computational fluid dynamics calculation
on the fluid patterns within cerebral aneurysm, flow sensor design and characterization as
well as flow rate measurements in a porcine artery.
3.3.1 TFN structure mechanics
The diamond pore TFN structure has lateral (L) and vertical length (W ) of 300 µm and
20 µm, respectively. The strut has lateral length (L1) of 56 µm and vertical length (W1)
of 24 µm with the membrane thickness (t) of 6 µm (Figure 24(A)). In order to express the
super-elasticity of the TFN, the user-defined shape memory alloy was employed as shown in
Table 2. The fracture limit of the maximum principal strain for the TFN was 12% [66].
Table 2: Materials properties of the TFN membrane [67]
Parameters Definition Value
Youngs Modulus Elastic modulus of the material 60 GPa
Poissons ratio Ratio of transverse contraction to longitudinal extension 0.3
Sigma SAS Starting stress value for the forward phase transformation 52000 psi
Sigma FAS Final stress value for the forward phase transformation 60000 psi
Sigma SSA Starting stress value for the reverse phase transformation 30000 psi
Sigma FSA Final stress value for the reverse phase transformation 20000 psi
Epsilon Maximum residual strain 0.07
Alpha Material response ratio between tension and compression 0
45
Figure 24(B) presents the computational and experimental results when the structure
is stretched up to 500% in the radial direction by a mechanical stretcher. Both the finite
element modeling and experimental results suggest that TFN has a negligible effect under
uniaxial stretching in the radial direction, which was verified by a highly accurate, electrical
resistance measurement with the hysteresis (relative resistance change: < 0.5%). The electri-
cal resistance is related to mechanical properties and integrity of the overall structure. The
initial electrical resistance shows variations due to the sample volume and electrical contact
points difference. The calculated maximum principal strain of the structure is 11.5% below
than the fracture limit and no fracture was observed during the experiment, which was con-
firmed by the measured electrical resistance in Figure 24(C). Overall, our result proves that
the TFN can be stretched in the radial direction more than 500% and thus can be deployed
in a blood vessel safely.
Figure 24(D) shows the maximum application strain of 17% where it reaches fracture
limit in longitudinal (axial) direction in the computational study. The experimental results
by optical microscope and electrical resistance measurement also agree with the modeling
results. The relative resistance measurement upon the strain change (Fig. 24(E)) verifies
the mechanical fracture at ∼17%. Three sets of tests demonstrate the mechanical response
of the membrane according to the applied strains are consistent with mild increase up to
∼12% and steep increase until completely fractured . Over the transition point, the TFN
structure seems to experience a localized necking and fracture. Experimental variations of
the alignment and integration of the TFN on the mechanical stretcher caused the difference
of the slope and resistance values in multiple tests.
The biaxial mechanical study (Figure 24(F)(G)) supports the uniaxial mechanical behav-
iors of the TFN, shown in Figure 24(D). The testing membrane was pre-stretched from 300%
to 360% in the radial direction and an additional strain in the axial direction was applied
to the structure with the increment of 2%. As long as the pre-loading was within the radial
strain limit of the TFN (∼500%), the amount of pre-loading did not directly affect to the
amount of variations in axial stretching. Overall results show a great agreement with those
from the uniaxial study, meaning that the pre-loading in the radial direction is negligible as
expected and the mechanical failure is governed by the axial stretching. This experimen-
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tal study reveals the structural safety of the TFN considering the direct integration with a
conventional backbone stent to form a cylindrical flow-diverter.
In addition, a series of the mechanical bending tests was conducted to estimate the
membrane integrity when the TFN is deployed in targeted, curved arteries (Figure 24(H),(I)).
The electrical resistance of the structure was measured when the curvature changed from 0 to
180 degrees. Both computational and experimental results show that multi-modal bending
does not cause any noticeable mechanical burdens on the structure. The calculated maximum
principal strain value in the modeling is less than 1% and the electrical resistance varies less
than 0.2% based on the repeated mechanical tests. The results present that the extremely
compliant TFN is capable of undergoing bending in the deployment and navigating through
the highly tortuous nature of neurovascular veins.
3.3.2 Determination of the junctions for a TFN flow-diverter
Figure 25 summarizes the evaluation of attachment patterns between a TFN and stent
backbone, based on the values of maximal equivalent stress and maximum principle strain.
A flow-diverter includes a TFN membrane and a stent backbone with several attachment
locations (Figure 25(a)). When deployed in the curved arteries, the hyper-elastic TFN
conforms to the geometry of the blood vessels. In this computational study, we modeled
a TFN (24 repeated diamond patterns) with several attachment junctions (Figure 25(b)).
The simulation model includes meshes with 303, 260 nodes and 157, 436 elements and
shows a high quality of the meshed elements. The TFN membrane has 200% pre-strains in
the radial direction. The faces of attachment locations are constrained in the longitudinal
direction to simulate the attachment of the TFN on the stent backbone. We compared three
representative patterns of glue joints to determine the optimal pattern when the same loading
was applied on the vertical direction to stretch the TFN structures (Figure 25(c)). Case 1
considers six glue joints in the vertical direction on both sides, which results in 2.6% of the
maximum principal strain (MPS) and 1.6 GPa of the maximum equivalent stress (MES).
Diagonal (case 2) and uneven (case 3) glue points show 4.5% (MPS), 2.7 GPa (MES) and
4.4% (MPS), 2.6 GPa (MES), respectively. As summarized in the table (Figure 25(d)), case
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1 shows the lowest MPS and MES compared to other cases. Thus, we choose the evenly
distributed, symmetric glue patterns that provides the highest structural safety upon the
given loading condition.
In addition to the determined glue pattern, we conducted another set of computational
study to find out the effect of the number of glue points to the structure. Figure 26 shows
five different cases with varying glue points from 10 to 2. To analyze the mechanical behav-
ior, the same loading was applied to the structures vertically and the MPS and MES were
compared. Figure 26(a)-(e) show the computational results with the applied loading and
Figure 26(f) summarizes the values of MPS and MES for five cases. The testing result sug-
gests to minimize the number of glue points for better structural safety upon the mechanical
stretching; two symmetrical glue points show only 1.7% of MPS and 0.9 GPa of MES.
3.3.3 Computational fluid dynamics (CFD) analysis in cerebral aneurysm
It can be observed from refaneurysm cfd that the flow in the aneurysm sac region adopts the
counterclockwise fashion, which means that the incoming flow will enter the sac at the distal
end and exit at the proximal end. Also Figure 27(c) demonstrates that the fluid velocity has
the maximum (in the range of 0.102-0.134 m/s) at the aneurysm neck and minimum (in the
range of 0.0029-0.0036 m/s) at the dome. These results match well with previous experimen-
tal results using particle image velocimetry systems [69]. Figure 27(d) and (e) also show the
static and dynamic pressure contour plots in the symmetry plane. The static pressure in the
sac region is similar to the parent vessel while the dynamic pressure is significantly reduced
from aneurysm sac to the dome due to the velocity drop. It confirms with the hypothesis
that static pressure is approximately uniformly distributed among the sac region while the
dynamic pressure or flow velocity should be monitored to assess hemodynamic quiescence
within the aneurysm sac. It also suggests that the ideal location for the microflow sensor
placement is near aneurysm neck to achieve the highest signals.
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3.3.4 Flow sensor flexibility characterization
Finite element analysis (FEA; ABAQUS CAE 2016, Dassault Systems, USA) was used to
design a highly compliant structure for a flow sensor. Considering the estimated defor-
mation during sensor integration, catheter insertion, and deployment, we focused on ultra-
stretchable and bendable building blocks. The computational model (Figure 23a) includes
an array of serpentine-like mesh patterns, configured in a ring-type structure for assembly
with a TFN and stent backbone. The model structure with seven sensor layers (bottom
elastomer, PI, metal, dielectric, metal, PI, and top elastomer) were meshed with C3D8R ele-
ments (8-node linear brick, reduced integration, and hourglass control) and the mesh quality
was monitored during calculation. In addition, an explicit dynamic method was employed
to model the highly nonlinear deformation under radial loading and bending (details appear
in Figure 23).
3.4 CONCLUSIONS
A flow-diverter can be deployed inside the targeted vessels for aneurysm treatment by oc-
cluding the incoming blood flows into the aneurysm sac. However, the hemodynamics inside
the aneurysm sac needs to be monitored in real time as the blood flows can re-enter the
aneurysm sac to cause the rupture. As the flow-diverter backbone is covered with a porous
TFN membrane, the flexibility of the TFN was evaluated using 3D computational study.
Different boundary conditions such as uniaxial, radial, biaxial and bending were applied
on a simplified TFN structure to examine the structure integrity. Both the computational
study and experimental results demonstrate that the TFN structure can undergo 500% radial
stretching and 17% longitudinal stretching without failure. Also TFN can survive extreme
bending up to 180◦ during the navigation in highly tortuous blood vessels. A computational
study was also employed to determine the optimal junctions on the TFN flow-diverter. The
results show that the number of glue points needs to be minimized for better structural
safety. The optimal flow sensor location was determined by a CFD calculations with an
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idealized aneurysm model. Then the flow sensor flexibility was modeled using Abaqus and
it shows 500% stretching in uniaxial and radial directions without failure. All the results
demonstrate the feasibility of a TFN flow-diverter integrated with a microflow sensing system
for aneurysm treatment.
The collective results for the flow sensor also show that an ultra-stretchable, implantable
flow-diverter system offers highly sensitive quantification of flow dynamics inside a blood
vessel. This flow sensing package allows an alternative post-treatment monitoring of the
intra-aneurysmal hemodynamics. There types of sensor materials including Au for a pro-
longed implantation, NiTi for a shape memory configuration and Mg as the transient use
were explored to demonstrate the system versatility. Both the computational and experi-
mental studies on the sensor flexibility demonstrated the system capability in a catheter-
assisted deployment in neurovascular vessels.The future work will include the development
of a miniaturized, wireless communication system based on the passive inductive coupling.
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Figure 24: Mechanical behavior of a TFN. (A) A geometric model of a TFN with dimensions
and meshed structure; lateral length: L = 300 µm and L1 = 56 µm and vertical length: W
= 20 µm and W1 = 24 µm. (B,D,F,H) Comparison between the FEM results and optical
and scanning electron microscopic images of a TFN for radial stretching (B), axial stretching
(D), biaxial stretching (F), and bending (H). (C,E,G,I) Plot of electrical resistances of a TFN
according to the applied strains (C,E,G) and the bending curvature (I). [68]
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Figure 25: Determination of the optimal junctions according to the attachment patterns. (a)
Optimal microscopic image of a TFN flow-diverter. (b) A TFN geometry for the FEM study.
(c) Three representative patterns of glue points (six locations) with the vertical stretching
for integration with a backbone stent. (d) Table summarizing the maximum principal strain
and maximum equivalent stress; case 1 shows the lowest values in both criteria.
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Figure 26: Determination of the optimal junctions according to the number of glue points.
(ae) Five different cases with different numbers of glue locations and their FEM results that
show the deformation patterns and the maximum principal strains. (f) Table summarizing
the maximum principal strain (MPS) and maximum equivalent stress (MES); case (e) shows
the lowest MPS and MES.
53
Figure 27: CFD results for the blood flow profiles with an aneurysm sac. (a) Geometry
model. (b) Velocity vector on the symmetry plane in the aneurysm model. (c) Velocity
contour on the symmetry plane in the aneurysm model. (d) Static pressure contour on the
symmetry plane in the aneurysm model. (e) Dynamic pressure contour on the symmetry
plane in the aneurysm model.
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Figure 28: (a) Radial stretching (up to 500%) of Au, Mg, and NiTi sensors. (b) Bending up
to 180◦ of Au, Mg, and NiTi sensors. Both results show negligible values from the maximum
principal strains.
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Table 3: Materials properties and calculated maximum principal strain (MPS) values. The
fracture limits of Au, Mg, and NiTi are 5% [74], 10% [75], and 12% [66], respectively.
Materials Young’s modu-
lus (GPa)
Poisson’s ratio MPS from 180◦
bending (%)
MPS from 500%
radial stretching
(%)
NiTi [70] 6 0.33 0.91 0.84
Mg [71] 4.5 0.35 0.91 0.89
Au [72] 79 0.4 0.98 0.94
Ecoflex
[73]
0.069 0.49
PI [68] 2.5 0.34
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4.0 COMPARTMENTALIZED STENT GRAFT TO ISOLATE THE
PERFUSION OF THE ABDOMINAL ORGANS
4.1 INTRODUCTION
One of the major obstacles facing organ transplantation has been the shortage of donor
organs. Despite over 120,000 patients in United States awaiting for organ transplant [76],
only 1 in 4 will actually receive one, leaving the remaining patients with the immense burden
of organ failure. Donation after brain death (DBD) or living donors have been considered
as the preferred source of donor organs and organ recovery is done under ideal conditions to
preserve organ function. As the combined number of DBD and living donors has plateaued
[77], the current organ shortage cannot be resolved within these donor groups and other
donor sources have been used to expand the organ donation pool.
Recent growth among donation after cardiac death (DCD) has represented a unique
option to significantly expand the organ donation pool [78, 79]. DCD donors include patients
with non-survivable injuries and cardiopulmonary life support is discontinued after family
consent for donation. The details of DCD donors are unique from other donor sources and
require that the consented donor first expire from a natural cardiac death after removal from
life support. It is ethically mandatory that nothing be done to expedite the natural death
of the donor and that organ recovery cannot proceed until after cardiac death. During this
interval blood pressure and oxygenation fall and is known as the agonal phase. When the
agonal phase exceeds 30-40 minutes, the organs are frequently discarded. In fact, despite
the increase in potential DCD donors over the past decade, the number of organs recovered
from DCD was only half of that observed in DBD donors [80]. Among those that are used,
there is a high rate of complications [81, 82, 83, 84, 85, 86].
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Ultimately the ability to increase the number of healthy donor organs is directly related
to the ability to maintain organ perfusion while the donors own blood pressure is low and
the blood is poorly oxygenated. The dilemma becomes how to maintain perfusion of the
abdominal organs without increasing cardiac stress and without surgery, in keeping with
ethical considerations. While several approaches have been described to deliver oxygen to
the organs [87, 88, 89, 90], these methods all alter the course of cardiac death they are
ethically prohibited before cardiac death. Since significant injury has already occurred by
the time of cardiac arrest, these post-mortem approaches have not impacted the outcome of
DCD organ donation.
Modern vascular therapies are increasingly delivered using catheter based techniques.
Aortic stent grafts, for instance, are used to remodel blood flow of the aorta during aneurysm
repair, but as a simple linear conduit, these offer no utility for improving DCD organ recovery.
We reasoned that the large size of the aorta and vena cava (large vein) would allow for a
stent with two compartments. A centre lumen would be similar to a traditional stent, while
the outer chamber would circulate oxygenated blood separate from the systemic circulation.
In this way, the oxygenated perfusion of the abdominal organs is insulated from the unstable
environment of the agonal donor.
In this study, we have demonstrated proof of concept results for a dual chambered stent
that isolates the perfusion of the abdominal organs from the circulation of the dying donor.
As proof of concept, we used commercially available iliac limbs and covered stents to create
a prototype dual chambered stent. As one of the key goals of this study, it was important to
demonstrate that the narrowing of the centre lumen to 50% of normal would not significantly
increase back pressure that would precipitate premature cardiac death.
A schematic illustrates the inadequate perfusion abdominal organs including liver, pan-
creas, bowels and kidneys during the agonal phase (Figure 29a). By contrast, with implan-
tation of a compartmentalized organ perfusion stent, the abdominal organs are continuously
perfused from an external chamber with blood that is oxygenated externally while the centre
lumen of the stent continues to carry blood flow from the agonal donor to the rest of the
body (Figure 29b). As a result, this feature will improve organ perfusion prior to withdrawal
of life support, yet would not commit the patient to organ donation until the time of car-
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diac death. The functionality of our prototype device was evaluated by measuring the flow
fields in localized regions using a computational fluid dynamics (CFD) investigation, as well
as by an in vitro measurement of local pressure alterations. In addition, we assessed the
collapsibility and deployment of our device both in vitro bench-top and in vivo swine tests.
Figure 29: (a) Irreversible injury of the abdominal organs as a result of low blood flow from
the failing heart. (b) The dual compartmentalised stent graft isolates the abdominal organs
with oxygenated flow perfusion while the natural cardiac death process is uninterrupted.
Device cross-section is shown in inset box.
4.2 MATERIALS AND METHODS
4.2.1 Creation of Organ Perfusion Stent (OPS)
Organ Perfusion Stent (OPS) for both the aorta (primary artery of the body) and vena cava
(primary vein) were fabricated using commercially available stent grafts in this study. For
the arterial OPS, two 12 mm diameter Dacron polyester iliac limbs seal zones (Cook, Bloom-
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ington, IN) were sutured with 5.0 - 8.0 nylon sutured to both ends of the 6 mm diameter
self-expanding stent graft (Viabahn stent, Gore, Flagstaff, AZ) under stereomicroscopy at
2.5 - 4.5 X magnification (SZ61, Olympus America, PA). Polytetrafluoroethylene (PTFE)
sealant tape (3M, St. Paul, MN) was used to reinforce suture lines. For the venous OPS,
two iliac stent grafts with a 12 mm center lumen and a tapered 23 mm seal zone (Cook,
Bloomington, IN) were sewn end to end with the 12 mm ends juxtaposed.
The total length of these two devices was 13 cm. Once both arterial and venous OPS
have been fabricated, an 80 cm long 10 Fr sheath (#G13033, Cook, Bloomington, IN) was
integrated into the device through a hole in the proximal flare of one end of the devices.
These sheaths would provide perfusion of the arterial or drainage of the venous external
compartments, respectively. The 10 Fr sheath was tightly affixed to the OPS with a 5.0 size
nylon suture and medical grade cyanoacrylate glue (MG30, ASI, Frankfort, IL). The distal
end of the 10 Fr sheath was located 2 cm below the distal flare area to ensure the sufficient
blood flow from the sheath. An additional superelastic nitinol mesh cage was manufactured
using superelastic thin wires (0.012” diameter wire, NDC, Inc., CA) via a high precision
mechanical bending and joining method, then subsequently added to the distal end of the
10 Fr sheath in order to prevent dynamic compression of the flow lumen. Both arterial and
venous OPS prototypes were collapsed using a stent crimper (RMC, Blockwise Engineering
LLC, AZ) after applying nitrogen gas (i.e., phase change to Martensite, malleable state) and
decreasing the temperature. The stents were deployed via an 18 Fr and 22 Fr sheaths (Gore,
Flagstaff, AZ). The prototype OPS is described in Section 4.3.1.
4.2.2 In vitro testing configurations
It is important to study how much the deployed stent affects the physiological hydrodynamic
condition. Among many, the pressure drop created by deployment of the stent is one of the
most important parameters because it directly impacts the work required of the heart. We
performed in vitro pressure measurements as illustrated in Figure 30(a). It consisted of two
separate loops: the main flow loop mimics the normal flow from the heart in the centre lumen,
while the side branch loop simulates the oxygenated blood flow to the external chamber of
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the stent. Figure 30(b) demonstrates the completed testing circuit based on the schematic.
A centrifugal pump (Biomedicus, Medtronic, Minneapolis, MN) was used to simulate cardiac
flow within the silicone tube while the peristaltic pump (FH100, Thermo Fisher Scientific,
Pittsburgh, PA) was to perfuse the external chamber. A flow meter (FLR1009-D, Omega
Engineering Inc, Stamford, CT) was placed adjacent to the outlet of the centrifugal pump to
monitor the corresponding flow rate inside the main flow loop. A differential pressure sensor
(Digi-Key Corporation, MN) with the range of ±500 Pa was connected to the pressure taps
between the inlet and outlet of our organ perfusion device to measure the pressure variance
across the device in the main flow. A DC power supply (GPS-4303, INSTEK America Corp.,
Montclair, CA) provided a 5 V voltage to the pressure sensor and an output voltage in the
range of 0-5 V was measured and then converted to the pressure difference using a linear
calibration curve.
Figure 30: (a) Schematic diagram of the in vitro local pressure measurements. (b) Testing
flow loops constructed based on the schematic diagram. The two ports on the organ perfusion
device were connected to the corresponding ports on pressure sensors (shown in white line).
De-ionized (DI) water instead of blood served as working fluid in the test circuit due
to the foaming and clogging issues of blood during the flow test. In order to evaluate the
pressure difference through the organ perfusion device versus the flow rate of the main flow,
the flow rate generated by the centrifugal pump was gradually increased from 0 to 250
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mL/min in a 50 mL/min increment, and the corresponding pressure difference was recorded.
Note that the flow from the centrifugal pump was approximated to be steady with constant
flow rates. This setting represented the control group. Then the peristaltic pump was also
switched on with increasing revolutions per minute (RPM) from 10 to 50 in increments of
10 and the corresponding pressure difference was monitored for pressure variations following
deployment of the organ perfusion stent. Note that the organ perfusion device is flexible
and deformable, which means the surrounding branch flow may affect the main flow. Also
in reality, a pulsatile flow with systolic/diastolic pressure 120/80 mmHg and 60 beats/min
will be more appropriate for human physiology conditions. However, the pressure difference
across the device will be varied with time frames and this imposes challenges to pressure
measurement.
4.2.3 Computational fluid dynamics (CFD) analysis
For two points along a streamline for incompressible flow in a tube, the Bernoulli equation
is given as [91]:
P1
ρg
+
v21
2g
+ z1 =
P2
ρg
+
v22
2g
+ z2 + ∆hf + ∆hm (4.1)
where P1 is the pressure at point 1, P2 is the pressure at point 2, ρ is the density of the fluid,
g is the gravitational acceleration, v1 is the flow speed at point 1, v2 is the flow speed at point
2, z1 is the elevation at point 1 and z2 is the elevation at point 2. The overall hydrodynamic
loss is contributed by two major parts: friction on the straight section and sudden change
in tube geometries.
∆hf is the head loss due to the friction and is given by the Darcy-Weisbach equation:
∆hf = f
L
D
v2
2g
(4.2)
where f is the friction factor, L and D are the length and diameter of the straight tube,
respectively. ∆hm is the minor head losses due to tube geometry changes in entries, exits,
fittings and valves and can be characterized by:
∆hm = ΣK
v2
2g
(4.3)
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where K is the loss coefficient. The current tube for the main flow has two geometry changes:
tapers with contraction and expansion. In between, a straight tube is placed.
For the tapered contraction, the diameter of the tube reduces from d2 to d1 along length
l, we can define
θ =
d2 − d1
2l
, β =
d1
d2
(4.4)
For θ ≤ 45◦,
K =
0.8sin θ
2
(1− β2)
β4
(4.5)
For 45◦ < θ ≤ 180◦,
K =
0.5
√
sin θ
2
(1− β2)
β4
(4.6)
Similarly, for the tapered expansion, the diameter increases from d2 to d1 along length l. For
θ ≤ 45◦,
K =
2.6sin θ
2
(1− β2)2
β4
(4.7)
For 45◦ < θ ≤ 180◦,
K =
(1− β2)2
β4
(4.8)
In order to visualize the fluid flow patterns within the device, both the arterial and
venous stents were modelled and meshed in ANSYS Workbench 15.0 Fluent (ANSYS Inc.,
PA, USA). Figures 31(a) and (c) illustrate the cross sections and dimensions of the arterial as
well as venous OPS. The arterial stent device had a diameter of 1.3 cm in the larger section
and diameter of 0.6 cm in the smaller section while venous stent device had a diameter
of 2.2 cm in the larger section and diameter of 1.1 cm in a smaller section. Both of the
devices had 2 cm long inlet and outlet regions, 10 cm long straight tube region and 1 cm
transition regions (diameter contraction/expansion region). Figure 31(b) and (d) show the
arterial stent model and venous stent model with meshed elements in ANSYS Workbench
15.0 Fluent, respectively. The entire fluid region within the OPS was partitioned into a series
of elements with nodes. The inlet velocity was assigned by using the flow rate equal to 250
mL/min. Liquid water from ANSYS Fluent material database was modeled with fluid density
ρ = 998.2 kg/m3 and viscosity µ =1.003×10−3 kg/(m·s). The blood flow of a dying patient
would expectedly decrease flow in the stent central lumen, with a reduction in the Reynolds
63
number and would be unlikely to deviate from laminar flow. Therefore, a laminar flow model
was assumed and a set of simultaneous governing equations were solved on different nodes
with pre-defined fluid properties and boundary conditions. We also assumed the device wall
to be rigid and would not contract or expand with the incoming flow in order to simply the
model into a pure fluid problem. The wall shear stress (WSS) for a Newtonian fluid is given
by
τwall = µ
∂u
∂y
∣∣∣∣
y=0
(4.9)
where µ is the dynamic viscosity, and ∂u/∂y at y = 0 is the velocity gradient on the wall.
Therefore, WSS distributions on the stent wall can also be derived from the obtained velocity
field.
Figure 31: (a) Dimensions of the OPS in arteries. (b) Meshed arterial stent model in ANSYS
Fluent 15.0 for CFD analysis. (c) Dimensions of the OPS in veins. (d) Meshed venous stent
model in ANSYS Fluent 15.0 for CFD analysis.
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4.3 RESULTS AND DISCUSSIONS
4.3.1 Prototype Organ Perfusion Stent (OPS)
Figure 32 illustrates the organ perfusion stent (OPS) for arterial and venous locations, re-
spectively. The arterial OPS (Figure 32a) has 29 cm total length, which includes two flare
regions (i.e., both in distal and proximal ends) for isolating cardiac blood flow from the
organ area as well as a long middle sections for delivering the oxygenate blood to several
organs. In order to prevent dynamic occlusion of the 10 Fr perfusion lumen, a nitinol mesh
cage was attached at the distal end of the perfusion sheath as shown in figure 32. The 10 Fr
sheath was attached along with the length of the arterial OPS confirming a tight integration
during collapsing and deployment. This 10 Fr sheath plays an important role for device
delivery, i.e., push rod. Over 10 times of collapsing and deployment testing with an 18 Fr
delivery sheath in vitro, there was no significant device failure or damage occurred during
the collapsing and deployment procedures. The venous OPS was similar to the arterial OPS,
but the dimensions were larger consistent with the increased diameter of this vessel.
4.3.2 Computational Fluid Dynamics Results
With the calculation settings described in section 4.2.4, figures 33(a) and (b) demonstrate the
fluid velocity contours within the arterial and venous OPS, respetctively. In arterial OPS
case, the averaged flow speed increased significantly by 470% when the fluid entered the
straight region from the inlet. A parabolic velocity distribution pattern with the maximum
of 0.23 m/s was observed at the outlet region in figure 33(a). The WSS was then calculated
from the velocity field and a maximum of 0.96 Pa was obtained on the boundary between the
end of the contraction and straight region (figure 33(b)). Similarly, the averaged flow velocity
increased by 290% when the fluid passed through the straight region in venous OPS case.
At the outlet region, the maximum velocity was 0.074 m/s, which is much lower than the
arterial OPS case. Also the WSS with a maximum of 0.18 Pa was obtained on the boundary
between between the end of the contration and straght region (figure 33(d)). In summary,
the arterial OPS exhibited both higher flow velocity and WSS as opposed to venous OPS
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Figure 32: (Prototype OPS devices. (a) OPS designed for aortic (arterial) placement. (b)
OPS for placement in the vena cava (venous).
with the same flow rate settings at inlet. This is due to smaller diameters in the arterial
OPS. In two cases, the magnitudes of WSS are minimal and we expect that these would not
be associated with anyserious injury of the endothelium or blood vessel wall [92].
4.3.3 In vitro Measurement of Local Pressure Alterations
For the arterial stent device, the pressure difference (in vertical axis) between inlet and outlet
versus flow rate in the main flow loop (in horizontal axis) is plotted in figure 34(a). This
baseline results of the flow loop without use of the organ perfusion stent represent the control
group. Figure 34(a) reveals a linear relationship between pressure difference and flow rate
with R2 equal to 0.9802. When the flow rate in the main loop increased from 50 mL/min to
250 mL/min, the pressure difference between inlet and outlet of the organ perfusion stent
increased from 0.23 mmHg to 1.56 mmHg, indicating that pressure difference only slightly
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Figure 33: (a) Calculated flow velocity contours in arterial OPS. (b) Calculated WSS con-
tours in arterial OPS. (c) Calculated flow velocity contours in venous OPS. (b) Calculated
WSS contours in venous OPS.
increased by 1.33 mmHg with 200 mL/min flow rate elevations. Compared to the normal
human blood pressure values (i.e., 120/80 mmHg), this pressure variation is negligible thus
the implantation of our organ perfusion stent would pose no increased work on the human
heart. Similarly, figure 34(b) presents the pressure difference when the perfusion procedures
were applied to the side branch. The flow rate generated by the centrifugal pump was fixed
at 200 mL/min. When the peristaltic pump rotation increased to 50 in a clockwise direction,
the pressure change in the main stream only slightly increased by 0.15 mmHg. In addition,
when the revolution direction in peristaltic pump was reversed, the change in the pressure
difference is 0.14 mmHg. In summary, we conclude that the deployment of the stent in the
artery and separate flow to the abdominal organs will generate a negligible load.
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Figure 34: Measured pressure drop across the arterial perfusion stent device. (a) Pressure
difference in arterial perfusion stent versus flow rate in the main stream without peristaltic
pump. (b) Effect of side branch flow on the pressure drop (the main flow rate was fixed at
200 mL/min).
We repeated the procedures described above in the venous stent device using the same
testing circuit configurations. Figure 35(a) summarizes the pressure difference (in vertical
axis) versus the incoming flow rate (in horizontal axis) and a linear relationship was also
observed with calculated R2 equal to 0.9372. When the flow rate in the main stream in-
creased from 50 mL/min to 250 mL/min, the corresponding pressure difference increased
from 0.12 mmHg to 0.39 mmHg, indicating that pressure difference only slightly increased
by 0.27 mmHg with 200 mL/min flow rate elevations in the main stream. The effects of
peristaltic pump on the pressure variations across venous stent device were also assessed
and the results were shown in figure 35(b). A negligible increase (0.16 mmHg) in the pres-
sure difference between inlet and outlet was observed when the peristaltic pump rotation
increased to 50 in a clockwise direction. While the revolution direction in peristaltic pump
was reversed, there was a 0.22 mmHg elevation in the pressure difference compared to the
control group. In summary, the simulated venous stent implantation and augmented flow to
the abdominal organs did not significantly increase heart strain. In conclusion, our in vitro
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pressure difference measurement suggests that implantation of the OPS into the vein would
not significantly impact cardiac physiology.
Figure 35: Measured pressure drop across the venous stent device. (a) Pressure difference
in venous perfusion stent versus flow rate in the main stream without peristaltic pump. (b)
Effect of side branch flow on the pressure drop (the main flow rate was fixed at 200mL/min).
4.3.4 In vitro Assessment on Device Delivery
Deployment of the arterial stent in vitro is shown in Figure 36 (a)1-5. Figure 36 a-1 demon-
strates the collapsed arterial OPS (along with the 5 Fr catheter for delivery over a guidewire).
By unsheathing the distal flare of the OPS was first deployed (a-2), then the distal end (with
the nitinol cage) of the 10 Fr sheath was exposed (a-3). Figure 36 a-4 demonstrates deploy-
ment of 80% of the long device, then, a-5 shows the proximal flare deployment completing
the device delivery.
Using a similar method, deployment of the venous OPS is shown in Figure 36(b) 1-5.
Figure 8 b-1 illustrates the collapsed venous OPS in 22 Fr sheath. The 5 Fr catheter for
guidewire delivery was not used here due to the bulkiness of the collapsed venous OPS device.
No device failures were observed after 10 times of in vitro repeated collapsing and deployment
tests. In addition, there was no 10 Fr sheath (i.e., push rod) migration (or failure) during
collapsing and deployment, which is critical for successful and accurate delivery of the device.
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Figure 36: (a) 15: Deployment of arterial OPS with a 10 Fr perfusion lumen. (b) 15:
Deployment of venous OPS with a 10 Fr perfusion lumen.
4.4 DISCUSSIONS
There are several limitations of our study. Our CFD calculations assumed the stent wall to
be rigid, i.e., the wall would not move with the fluid and no expansion or contraction was
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considered. However, the flexible graft materials covering the stent backbone will undergo
expansion when the fluid enters the narrow straight region. Therefore, a fluid-structural-
interaction model should simulate more realistic conditions. DI water instead of blood was
used as the working fluid in the in vitro pressure measurement. Blood has fluid density
ρ=1.025 kg/m3 and viscosity µ =3.5×10−3 kg/(m·s), which is actually 3.5 times of the DI
water. Using a simple laminar model, the pressure drops with blood would be about 3
times higher than those with water assuming the blood viscosity is 3 times higher than that
of water. Even accounting for this, the pressure drop in blood flow is less than 1 mmHg,
which is still a minimal load to the heart. Also a pulsatile pump with systolic and diastolic
pressure mimicking human conditions instead of constant flow should be used in order to
monitor dynamic pressure variances. Our future work will include further evaluation of
device functionality in vivo with advanced dynamic pressure monitoring platforms.
4.5 CONCLUSIONS
In this paper, we designed a novel compartmentalized stent graft to isolate the abdominal
organs from ischemic injury. The two prototype organ perfusion stent grafts were fabricated
for arterial and venous placement, respectively. One theoretical ethical concern is that
the narrow section of the stent may increase back pressure and, in turn, cardiac stress,
against ethical principles of the DCD donor. We examined pressure increases during device
deployment in vitro and found only a negligibly small increase in local pressure drop across
both the arterial and venous stent. These findings were consistent with our CFD estimates.
The CFD analysis also showed that the local shear stress on the device is much smaller than
the physiological condition. We conclude from these results that deployment of the stent
would not significantly increase cardiac strain. The in vitro deployment test observed no
device failure after 10 cycles and the device placement studies in swine model confirmed no
gross vessel wall injury.
Traditional catheter approaches can certainly be used to cannulate the individual visceral
vascular branches that perfuse the abdominal organs but obligates potentially hazardous in-
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travascular contrast agents and requires the critically ill donor to be transported outside
of intensive care unit. By contrast, the dual chambered stent rapidly consolidates multiple
branches into a single compartment simplifying deployment in less than a minute. Clini-
cally other applications of this approach may include delivery of medications directly to the
abdominal organs that might otherwise have adverse effects if given systemically.
In conclusion, we believe the further development of dual chambered stents may offer the
ability to increase the number and quality of livesaving donor organs for transplant while
respecting key ethical considerations.
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5.0 A RETRIEVABLE RESCUE STENT GRAFT FOR
NONCOMPRESSIBLE HEMORRHAGE CONTROL
5.1 INTRODUCTION
Patient specific instrumentation (PSI) was introduced in the last several years to obtain a
customized implant fit for patients with greater accuracy and shorter rehabilitation time
as a growing trend in personalized medicine [93]. For example, PSI has emerged as a new
technology in total knee arthroplasty (TKA) as a replacement for the traditional instrumen-
tation [94]. The medical implantsmanufactured from magnetic resonance imaging (MRI),
computed tomography (CT) imagery, or a combination, are specifically designed for the
patient and intended to offer a faster, more accurate, and cost-effective surgery.
Recent advances in 3D printing have provided a new option to manufacture the patient-
specific medical devices such as dental, spinal, and hip implants [95, 96, 97, 2, 98, 99].
Without the need for the surgeons to modify the implants into a desired shape, size and fit
for the patient, implants and prostheses can be quickly produced and customized through
the translation of X-ray, MRI and CT scans into digital print files [2]. It was reported that
3D printed customized implants can reduce the length of surgery time, reduce the risks of
complications such as infections, and improve clinical outcomes [100, 101, 102]. While the
future of 3D printing in medical implant applications is promising, for endovascular devices,
which typically consist of ultra-thin metallic structures and polymeric membranes [103],
there remain significant logistical issues for 3D printing. Typical endovascular devices need
to be collapsed into a low-profile catheter with the diameter of a few millimeters for delivery
and then deployed in the targeted vascular system up to 3 centimeters. It requires flexibility
to accommodate dramatic device diameter reduction and subsequent expansion, sufficient
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structural mechanical strength (e.g., radial force) to prevent device migration inside the
vessels, and a smooth surface contact with the tissues to lower the risks of inflammation.
These requirements cannot yet be fulfilled by current 3D printing technologies [104, 105, 106].
Some of the endovascular devices require ultra-thin polymeric membrane, commonly
(expanded) polytetrafluoroethylene (ePTFE) [107, 108, 109, 110, 111, 112, 113, 114], to
cover the metallic-framed backbone because it has relatively high tensile strength, controlled
porosity, low surface energy, and superior hemocompatibility. This is often done by fabri-
cating the membrane separately and then integrating it with the metallic frames. As the
conventional polymeric membranes have already been set with pre-defined geometry and di-
mensions, modifications often need to be performed by the surgeons to tailor to the specific
patient needs. It significantly lengthens the operation time and might increase the complica-
tions as well. Therefore, an approach to customize existing PTFE tubing would be beneficial
to manufacture patient-specific endovascular devices within a clinically relevant timeframe.
Aside from clinical use, rapidly customizable PTFE sleeves are virtually indispensable for
research on custom endovascular devices. By using this approach, our group was able to
quickly adapt PTFE to evolving needs and complicated sizing configurations, where other
custom approaches would have introduced both significant delay and cost.
In this study, a rapidly customized expanded polytetrafluoroethylene (ePTFE) tube was
investigated after combination with a laser-welded nitinol frame to create a stent graft. This
device is intended for military or civilian vascular trauma, to be introduced and deployed
endovascularly to rapidly control bleeding [115]. An important feature of this stent is that it
allows for retrieval at the time of permanent repair, thus avoiding complications of current
permanent stents that may be misplaced under emergency circumstances [116].
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5.2 METHODS
5.2.1 Material selections
Two types of materials were selected to fabricate the customizable stent graft for the vas-
cular injury management, including (1) highly stretchable expanded polytetrafluoroethylene
(ePTFE) as the stent covering membrane and (2) superelastic thin nitinol wires as the
metallic backbone. An extruded ePTFE tube (ZEUS, Inc., Orangeburg, SC) with an inner
diameter of 0.394” ± 0.004” and a wall thickness of 0.005” ± 0.004” was used to cover the
nitinol stent backbone for the study. The mechanical properties of the tube were investigated
in the following section. The cold-drawn superelastic nitinol wire (Confluent, Fremont, CA)
with diameter of 0.0155” was used for the stent backbone fabrication. The transformation
temperature of the nitinol wire is between 5 and 18oC, which is ideal for the superelastic
behavior in the body temperature. Both ePTFE and nitinol are well-known biocompatible
materials and widely used in endovascular devices including stents, stent grafts, occluders,
guidewires and vascular filters.
5.2.2 In vitro and in vivo tests for evaluating devices functionality, feasibility,
and biocompatibility
5.2.2.1 Mechanical characterization of ePTFE membrane The stress-strain be-
havior of the ePTFE membrane was measured with a mechanical testing system (FMS500,
Starrett, MA). The 0.005 thick (thickness T ) ePTFE samples were cut into 25 × 25 mm
(length L × width W ) size and affixed to the two film test grips (G1008, Mark-10 Co., NY),
one movable on the top and while another fixed on the bottom (Figure 37(a)). The two grips
were aligned carefully and the distance between two grips (D) was measured to calculate
the strain. The grips on the top were connected to a load cell with the capacity of 500 N
(FLC-500E, Starrett, MA) to measure the corresponding tensile force (F ). As the ePTFE
membrane exhibited anisotropic stress-strain behaviors, i.e., the membrane is less stiff (or
easily stretched) in radial direction (along the length) than the longitudinal direction (along
the width), the stretchiness tests in both radial and longitudinal directions were performed.
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The travel displacement (∆D) of the top grips was set as 40 mm with the velocity of 4
mm/min and 10 mm with the velocity of 1 mm/min for radial direction and longitudinal
direction, respectively. The sampling rate was 100 Hz and a tablet connected to the me-
chanical testing system recorded the travel distance (∆D) and load force (F ) in real time.
The stress (σ) and strain () of the ePTFE membrane can be calculated from
σradial =
F
W · T
σlongitudinal =
F
L · T
 =
∆D
D
(5.1)
Figure 37: (a) Set-up for the mechanical stretching of the ePTFE membrane to measure the
stress-strain behaviors; (b) Set-up for the ePTFE sweat test in vitro.
5.2.2.2 Porosity calculation with the applied strain The ePTFE membrane was
stretched radially to 200%, 400% and 550% (before fracture) using the methods described
in section 5.2.2.1. Four samples including original (non-stretched), 200% stretched, 400%
stretched and 550% stretched ePTFE membranes were characterized by scanning electron
microscopy (SEM-ZEISS Sigma500 VP, Carl Zeiss Microscopy, LLC, NY) after 45 seconds
sputter deposition of thin Palladium layer. The SEM images with 1000x magnifications were
imported into Matlab R2014a as the matrices of greyscale values. The number of pixels on
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the ePTFE fiber region was counted in the matrices so the porosity of the ePTFE membrane
with different stretchiness levels can be calculated from
porosity = 1− number of pixels on fiber regions
total number of pixels
(5.2)
5.2.2.3 In vitro sweating test for evaluating potential leakage of ePTFE mem-
brane Figure 37(b) shows the in vitro test setup for determining the ePTFE radial stretch-
iness with respect to the applied pressure induced by the incoming flow. The ePTFE tube
was cut into 10 cm long with one end completely sealed using glue. Another end of ePTFE
tube was connected to a pressure sensor (PRESS-S-000, PendoTECH, NJ) to measure the
corresponding fluid pressure inside the ePTFE tube. The heparinized pig blood was used
as the working fluid inside the test circuit and a syringe pump was utilized to generate the
continuous blood flow into the ePTFE tube. The flow rate was set as 50 mL/h. At the
pressure levels of 30, 60, 90 and 120 mmHg, the corresponding ePTFE tube diameter as well
as length were measured respectively and plotted against the pressure level changes. The
test was repeated three times to calculate the average and standard errors. At the meantime,
the ePTFE tube surface was monitored for monitoring any blood leakage during the tube
expansion.
5.2.2.4 In vitro early thrombosis evaluation of ePTFE Three sets of ePTFE sam-
ples (5mm x 5mm) were prepared with pre-stretchiness of 0%, 200% and 400%, respectively,
to be fixed on the glass substrate and placed in the petri dish. Each set of 3 samples were im-
mersed into the fresh blood directly drawn from the living pig (i.e., non-heparinized blood) for
1, 2.5 and 5 minutes to assess the early thrombotic response of the ePTFE. Then the samples
were gently rinsed with saline immediately. The following protocols were used to fix the red
blood cells on the ePTFE polymer surface for SEM purposes: 1) add 2.5% glutaraldehyde on
sample surface for 5 minutes at room temperature and rinse with phosphate-buffered saline
(PBS); 2) place the samples in 30%, 50%, 70%, 90%, 95% and 100% ethanol successively for
5 minutes each at room temperature; 3) place the samples in 100% ethanol for 5 minutes; 4)
add hexamethyldisilazane (HDMS) on sample surface and incubate for 5 minutes; 5) remove
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HDMS and the leave the samples dry in the room temperature. Then the samples were
coated with palladium and subsequently characterized by SEM. As a control, we repeated
the process described above using heparinized pig blood and the blood cell adherence on
ePTFE sample was observed under SEM.
5.2.2.5 Finite element analysis (FEA) of nitinol stent crimping process The
stent crimping modeling was performed in Abaqus CAE 2016. Figure 38(a) shows the 3D
model used in the finite element analysis. Note that the stent model was simplified with a
constant diameter cylindrical design, while the prototype has a tapered design based on the
anatomy of the swine model. The crimper function was modeled with SFM3D4R elements
(4-node quadrilateral surface element with reduced integration) and the stent backbone was
modeled with 20,890 C3D8R elements (8-node linear brick element with reduced integration
and hourglass control). The element quality was checked using the mesh verification to
avoid mesh distortion. The nitinol material property was defined as Youngs modulus E =
60 GPa and Poissons ratio ν = 0.3 [70]. The contact between the crimper and the stent
backbone surface was defined as frictionless in the tangential direction and hard contact in
normal direction so the stent will be crimped along with the crimper diameter reduction. A
displacement loading normal to the crimper surface with magnitude up to 40% of the stent
diameter was applied on the crimper outer surface (Figure 38(a)) and the corresponding
stress/strain distribution as well as reactional radial force was calculated from the software.
5.2.2.6 In vitro radial force measurement of nitinol backbone A stent crimping
experiment was conducted to quantify the radial force of the prototype superelastic nitinol
stent backbone in vitro. Figure 38(b) and 38(c) show the measurement configurations using
the mechanical testing system. Dacron was selected as the crimper material due to its
mechanical property. One end of the Dacron strap (Sailrite Enterprises, Inc., IN) was glued
to the stainless steel bar at the bottom while the opposite end was clamped firmly by a
grip connected to a load cell. The Dacron strap was wrapped around the stent backbone
and exerted forces on the stent surface to crimp it approximately radially as the moving
stage pulled the Dacron strap up with the displacement magnitude equal to 40% of the
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Figure 38: (a) 3D model of stent backbone and boundary conditions for stent crimping in
Abaqus, (b) (c) experimental set-up to measure the radial force of the stent backbone, (d)
experimental set-up for stent pullout force in a silicone tube.
stent perimeter. The start position where the Dacron strap just had contact with the stent
backbone was determined when the measured load force first exceeded a small threshold
value of the load cell. Both the displacement and hoop force can be measured from the
mechanical testing system. Then the radial force can be calculated from the hoop force
using the following equation [117]:
Fradial = 2 · pi · Fhoop (5.3)
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The radial force with respect to stent diameter reduction (%) was plotted and compared
with the FEA results. As the prototype stent has a tapered design (i.e., the diameter in the
distal strut region is larger than the proximal strut region), we measured the radial force in
these two regions separately.
5.2.2.7 In vitro force analysis and measurement to assess device migration
When the stent graft was deployed inside the vessels, the contact pressure can be calcu-
lated using the following equation with an elastic cylinder compressed into another cylinder
model [118]:
Pc =
δ
R
[
1
Eo
(
r2o+R
2
r2o−R2 + νo
)
+ 1
Ei
(
R2+r2i
R2−r2i
+ νi
)] (5.4)
where δ is the overlap, R is the nominal radius, ro and ri is the inner radius of the outer
cylinder (vessels) and inner cylinder (stent graft), respectively. And Eo, νo, Ei, νo is the
Youngs modulus and Poissons ratio associated with outer cylinder and inner cylinder ma-
terials. Then the pullout force of the stent graft inside the vessels to determine the stent
migration can be calculated from [118]:
F = µ(Pc × A) (5.5)
where F is the pullout force, A is the contact surface area, and µ is the coefficient of friction.
In order to evaluate the stent migration inside the vessels, we measured the pullout force
of the stent backbone from the silicone tube to mimic the stent dislocation (Figure 38(d)).
The prototype stent backbone was collapsed into silicone tubes with the inner diameter of
0.5 and 0.75, respectively, i.e., the oversizing of the prototype stent backbone is about 51%
and 27%. The silicone tubes were fixed using a clamp on the bottom and the upper end of
the stent backbone struts was clamped by a gripper connected to a load cell. The moving
grip pulled the collapsed stent backbone out of the silicone tube by the distance of 4 mm
with the velocity of 1 mm/min and the travel distance as well as corresponding pullout force
in real time were measured and plotted.
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5.2.3 Stent graft fabrication process
A nitinol stent backbone was mainly fabricated using a precision micro-laser welding process
with the mechanical bending process [115, 119]. Two nitinol wires were bent to 60o angle
for easy fabrication of the first section of the backbone. The bent wires were welded side
by side making a perfect cylindrical geometry of the first section. Then additional crossed
welding spots were created at every 2 cm location by aligning the two wires side by side.
The intensity of laser is 1.4 kW, time for laser excitation is 1.2ms, frequency is 3 Hz with
step function waves, and spot size is 700 µm. Anatomically relevant aluminum mandrel
was prepared using a conventional turning process for thermal shape setting of the laser
welded nitinol backbone. The laser welded nitinol backbone was placed over the aluminum
mandrel and tightly fixed with 0.015 Ga iron wires (Malin Co., OH). Thermal shape setting
was performed under 500 oC for 40 min in the high temperature furnace (Lindberg/Blue M
Moldatherm Box Furnace, Thermo Scientific, PA), and subsequently rapidly cool down in
25 oC deionized water bath for 5 min. The nitinol backbone was removed from the mandrel
for the integration with ePTFE covering membrane. Prior to the ePTFE covering process,
two Tantalum (Td, Goodfellow, Huntingdon, UK) radiopaque markers were rolled from 30m
thick foil, then, attached on both distal and proximal ends of the device.
Once the nitinol backbone is fabricated, ePTFE covering membrane should be prepared
for the stent graft (Figure 39(a)). The 5 mm diameter ePTFE tube was stretched using 20-
26 mm diameter balloon catheters (Z-MED Balloon Dilatation Catheter, B. Braun Medical
Inc., PA). The length of balloon is 4 cm, therefore the balloon inflation was conducted several
times for stretch the entire length of the tube. After the initial stretch of ePTFE tube using
a balloon catheter, the tube diameter was tailored manually (Figure 39(b)). The stretched
ePTFE tube was covered on the nitinol backbone and fixed using a biocompatible polymer
adhesive (Loctite 4011, Henkel, Germany).
5.2.4 In vivo test with swine model
Yorkshire pigs (n=7) were placed under general endotracheal anesthesia as part of a Univer-
sity of Pittsburgh approved IACUC protocol with inhaled isoflurane. Abdominal exposure
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Figure 39: ePTFE covering process: (a) preparation of nitinol backbone and unexpanded
ePTFE tube and (b) expanded ePTFE tube based on the anatomy of the animal model after
three-step expansion
was obtained by an abdominal incision with exposure of the infrarenal vena cava (large
abdominal vein). The animals were heparinized with 100 units/kg of heparin to simulate
post-traumatic coagulopathy and as required by the porcine model due to rapid clotting of
this model at baseline. Following 18 G needle access of the infrarenal vena cava, the seldinger
technique was used to injure the cava with a 22 French dilator. The right femoral vein was
accessed under ultrasound guidance followed by placement of a long 9 French sheath (Oscor,
Palm Harbor, FL) by the seldinger technique. A 23-mm diameter and 10 cm long caval
stent graft was delivered through the sheath and placed below the level of the renal veins
under fluoroscopic guidance. Stent deployment was achieved by withdrawal of the vascular
sheath while holding the wire stem of the stent stationery. A venous angiogram was then
performed to document the vascular injury, stent control of the hemorrhage, and preserved
flow beyond the stent. In the final step, the stent graft was retrieved by advancement of the
vascular sheath to collapse the stent graft.
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5.3 RESULTS
5.3.1 Results on ePTFEs material behaviors
5.3.1.1 Stress - strain behavior Figure 40(a) and (b) show the stress-strain behavior
of ePTFE membranes under the tensile test using the test setup described in Section 5.2.2.1.
The ePTFE membrane was stretched in radial direction of the tube, reaching the fracture
strain of approximately 550% and the corresponding stress of 0.7 MPa (Figure 40(a)). This
outcome demonstrates that the ePTFE membrane can be easily stretched up to 550% after
the necking occurred during the tensile loading without mechanical failure. While there is
no mechanical failure, there is changed structure of the fibers in ePTFE after the elonga-
tion. Detailed ePTFE structure analysis will be discussed in the next Section (41). Figure
40(b) shows the stress-strain behavior when the ePTFE membrane was stretched in longi-
tudinal direction of the tube. The fracture occurred approximately at 8% strain and the
corresponding stress at fracture was as high as 23 MPa.
Figure 40: Stress-strain behavior of ePTFE membranes in tensile loading; (a) stress-strain
curve in radial direction of the ePTFE tube; (b) stress-strain curve in longitudinal direction
of the ePTFE tube
5.3.1.2 Porosity changes with applied strains in ePTFE Figure 41(a)-(d) present
the SEM images of ePTFE membranes with 1000x magnifications under 0%, 200%, 400% and
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550% applied strains, respectively. Figure 41(e) show the calculated porosity from Matlab
with respect to the various applied strains. As can be seen, non-stretched ePTFE membrane
exhibits an aligned dense microfiber structure with only 3% porosity that shows the adjacent
fibers stay within a very small gap. With the increased strain in the radial direction of the
tube, the gaps between fibers tend to be enlarged exhibiting a higher porosity of 14.4% and
20.87% in average for samples with 200% and 400% strain, respectively. In addition, the
multi-layers of ePTFE fibers were stretched differently, therefore, wrinkled and relatively
unorganized structures were found as shown in Figures 41(b) and (c). As the applied strain
reached 550%, the gaps between fibers had the maximum of approximately 30 µm in length
with 24.15% porosity in average, but the fiber networks were still connected and no fracture
was observed under the fracture strain value. Both the qualitative and quantitative analysis
on the SEM images have demonstrated that the structure porosity tends to increase along
with the applied radial strain, but will reach plateau of 26% before the fracture occurs.
5.3.1.3 Sweating test results of ePTFE Figure 42(a) shows the ePTFE tube con-
nected to the pump that is initially perfect cylindrical shape with the diameter of 5 mm
without any stretch. While the pump pushes the blood into the tube, the ePTFE tube
slowly expands with enlarged the pore sizes. Figure 42(c) shows the ePTFE tube diameter
changes with the incoming blood from the syringe pump, which indicates the stretch levels
of the ePTFE tube. The averaged diameter of the tube was significantly increased from
8.21mm to 21.97mm, 167% tube expansion as the fluid pressure elevated to 120 mmHg. No
fracture or leakage was found at this level of pressure since the fracture strain of ePTFE
polymer is higher than 500% in radial direction. Similarly, the ePTFE tube tends to be
shortened during the expansion, and Figure 42(d) shows the length reduction with respect
to the fluid pressure. Here, length reduction is denoted as the fraction of ePTFE tube length
changes to the original length. At the pressure level of 120 mmHg, the ePTFE tube length
decreased by about 8%, which is minimal compared to the significant diameter expansion.
Hence, there is no sweating (or leakage) issue on the stretched ePTFE tube, which demon-
strates that the tube can be used for the stent graft in the body where the applied pressure
level is approximately 120 mmHg.
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Figure 41: SEM images of ePTFE membranes with applied strain of 0% (a), 200% (b),
400% (c) and 550% (d) in radial direction under 1000x magnification. (e) (f) the calculated
porosity changes with respect to applied strain.
5.3.1.4 Assessment of the early thrombogenic response of ePTFE Figure 43(a)
shows the SEM images of non-heparinized blood product adherence on the ePTFE surface
with 0%, 200% and 400% stretchiness levels for 1, 2.5 and 5 minutes, respectively. The
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Figure 42: (a) ePTFE tube before the sweat test; (b) expanded ePTFE tube after the test;
(c) ePTFE tube diameter changes with respect to fluid pressure; (d) ePTFE tube length
reduction (%) with respect to fluid pressure.
number of blood cells (i.e., mostly red blood cells) adhered on the ePTFE surface increased
significantly as the immersion time into the fresh pig blood increased from 1 minute to 5
minutes. It confirms that more blood cells will grow onto the ePTFE surface if it has contact
with the surface for a longer period of time. For medical device applications, these results
suggest minimizing the device exposure to the blood in order to reduce the risks of thrombosis
on the device surface. Figure 44(b) also demonstrates that there was no significant difference
on blood cell attachment on ePTFE surface for different stretchiness levels. For the stent
graft fabrication, the ePTFE membrane will be expanded before wrapping onto the stent
backbone and in vitro results showed stretchiness level has no influence on the thrombosis
formation.
While the blood products adherence study with non-heparinized blood is important to
assess the hemocompatiblity of the material used in the stent graft (i.e., ePTFE), identical
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Figure 43: (a) Representative SEM images of early thrombosis on three sets of ePTFE
samples after 1, 2.5 and 5 minutes in vitro under 5000x magnifications using fresh non-
heparinized pig blood. (b) Number of cell counts on ePTFE samples after 1 2.5 and 5
minutes.
study is needed with heparinized blood because anticoagulant solutions frequently injected to
the blood stream during the endovascular procedure. Figure 44(a) shows the representative
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SEM images of blood cells adhrerence on ePTFE sample surface with heparinized blood.
As the blood are less prone to coagulate on ePTFE surface with heparin treatment, all the
samples with 0%, 200% and 400% stretchiness exhibit clean surface with minimal or no blood
cells visible when the samples were immersed in heparinized blood for 1, 2.5 and 5 minutes,
respectively. Figure 44(b) summarizes the count of blood cell attachment on the sample
surface. It can be observed that the blood cells with the heparin treatment are less likely
to be attached on the ePTFE sample compared with the blood cells from the one without
heparin treatment. Again, this outcome demonstrate there is no significant influence of the
stretchiness levels for the hemocompatiblity.
5.3.2 Results on nitinol backbones mechanical behaviors
5.3.2.1 FEA results of crimping process of the nitinol backbone Figure 45(a)
and (b) show the computationally modeled stress and maximum principal strain (MPS)
field when the stent backbone was crimped by up to 40% considering the targeted vessel
size. The maximal stress is 456 MPa and the maximal MPS is 0.6%, which is below the
fracture strain of nitinol [68]. Therefore, our nitinol backbone can be crimped down to 60%
of the original size successfully without any mechanical failures. Also, as we can see from
the calculated stress and strain fields in FEA results, the junctions of the struts exhibit both
highest stress and strain values while the straight struts exhibit relatively negligible stress
and strain values. Abaqus also calculated the corresponding radial force exerted by the stent
backbone during the stent crimping process at the diameter reduction of 10%, 20%, 30% and
40% and Figure 9(c) plots the radial force against stent diameter reduction (yellow line).
It can be observed that the radial force increased from 0.60 N to 2.98 N when the stent
diameter reduction increased from 10% to 40%.
5.3.2.2 In vitro measurement of the radial force Figure 45(c) (green and blue
dots) show the measured radial force using the test setup described in section 5.2.2.6. As the
nitinol backbone has a tapered design, we measured the radial force in large section as shown
in blue dots (distal end) and small section as shown in green dots (proximal end) separately.
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Figure 44: (a) Representative SEM images of early thrombosis on three sets of ePTFE
samples after 1, 2.5 and 5 minutes in vitro under 5000x magnifications using heparinized
fresh pig blood. (b) Number of cell counts on ePTFE samples after 1 2.5 and 5 minutes.
The large section exhibits a higher radial force compared with the small section, as the large
section experiences a higher strain deformation when the both sections are crimped into the
same diameter size. As can be seen from the plots, the radial force increased from 0.75 N
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Figure 45: (a) (b) Computed stress and strain distributions during stent crimping anal-
ysis in Abaqus. Unit of stress: MPa. (c) Calculated radial force from FEA and in vitro
measurement. (d) Measured pullout force in two silicone tubes with ID of 0.5 and 0.75.
to 2.83 N for small section when the stent diameter reduction ramped from 10% to 40%.
Similarly, the radial force value was from 0.94 N to 3.46 N for large section. The FEA results
matched well with the experimental results.
5.3.2.3 In vitro force analysis and measurement to assess device migration The
pullout force can be defined as the frictional force between the artery wall and the stent graft
during the stent movement. Here, we used a silicone tube for the artery model. The measured
pullout force of the stent backbone inside a silicone tube with ID of 0.5 (green line) and 0.75
(blue line) was plotted in Figure 45(d). From the plot we can see that the pullout force in
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a silicone tube with ID of 0.5 (51% oversizing) is about 2.65 N, which is much higher than
the one in a 0.75 (27% oversizing) tube (0.79 N). The pullout force is related to the contact
pressure between the collapsed stent and the tubes and a higher pullout force inside the tube
presents lower risks of stent migration inside the targeted vessels during the treatment. On
the other hand, the higher contact pressure also presents high risks of damage to the vessel
walls.
5.3.3 Stent graft prototype
Nitinol stent backbone was fabricated using a precise micro-laser welding process and sub-
sequently Td radiopaque makers were attached on both distal and proximal ends as shown
in Figure 46(a). The micro-laser welding technology for the nitinol wire enables the stent
backbone fully customizable since both the spot welding in narrow regions and thermal shape
setting process can easily tailor the geometry customizing the backbone structure. For the
in vivo studies, two prototypes have been successfully fabricated, which were smoothly col-
lapsed and inserted in 8-9Fr delivery sheaths (Figure 46(b)). Two types of prototype devices
are shown in Figure 46(c)-(f). Figure 46(c) and (d) show the nitinol backbone covered by
ePTFE from outside. The expanded ePTFE by ballooning was placed over the collapsed
nitinol backbone, then the backbone was deployed. A biocompatible polymer adhesive was
minimally applied in each welded locations. Figure 46(e) and (f) show the nitinol backbone
covered by ePTFE inside. The expanded ePTFE was placed inside the deployed nitinol
backbone for attaching the membrane on the nitinol backbone. As can be seen in the panel
inside the Figure 46(e), the polymer adhesive was applied everywhere the nitinol wires meet
with the ePTFE membrane to securely attach the membrane.
The first prototype (Figure 46(c) and (d)) showed slightly better performance for pre-
venting blood vessel bleeding, however, some portion of ePTFE membrane were caught by
the sheath during the retrieval process. One advantage of this device is that the nitinol
backbone consistently exerts its radial force, so the application of the polymer adhesive
could be minimized, which is beneficial for highly collapsible structure with two different
materials (i.e., nitinol and ePTFE). The second prototype shown in Figure 46(e) and (f)
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showed no potential ePTFE catching issue because the ePTFe membrane is surrounded by
nitinol backbone which collapsed outside. While the inside covered stent graft showed simi-
lar (or slightly lower) performance in terms of bleeding prevention, there are potential issue
of the detachment of the ePTFE membrane from the nitinol backbone during the collapsing
and deployment processes because all interfaces between nitinol and ePTFE were attached.
Therefore, both type of devices were used in in vivo swine tests and have successfully demon-
strated the feasibility and safety of the device, even though there are a few minor issues that
would not deter the tests.
Figure 46: Prototype devices; (a) nitinol backbone with Td radiopaque makers, (b) collapsed
device in 8-9Fr sheath, (c) side view of the device (outside covered), (d) front view of the
device (outside covered), (e) side view of the device (inside covered), and (f) front view of
the device (inside covered)
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In vitro device performance test has been performed by evaluating the deployment and
retrieval process. Figure 47(a) through (i) show the snapshot images of the in vitro test
results on the deployment and retrieval processes of the device with a 9 Fr delivery sheath
prior to the animal tests. Since the inside covered stent graft showed same performance of the
outside covered stent, only the outside covered devices results are shown here. Figure 47(a)
shows the fully collapsed device within a 9 Fr sheath for the venous stent graft. The sheath
was withdrawn after holding the extension wire of the stent graft stationery and continued
until all the device portions were deployed from the sheath (Figure 47(b)(d)). Once the
device is fully deployed, the retrieval process can be tested by pulling the extension wire
after holding the sheath in stationery to recapture the device (Figure 47(e)(i)). All device
portions are fully collapsed and inserted within the sheath for retrieval process (Figure 47(i)).
No significant visual damages or structural issues were found after 10 times repeated tests.
Figure 47: Device deployment and retrieval process using a 9Fr delivery sheath and outside
covered stent graft.
5.3.3.1 Gross look of the device and SEM image analysis Figure 48(a) and (b)
show the gross look of the harvested stent graft used in vein of the swine. As one can see in
the images, there are some locations where partially detached ePTFE membrane from the
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nitinol backbone observed after the device deployment and retrieval. The devices surface
looks mostly pristine except a few locations where the thrombosis was formed. This issue has
been resolved by adding a few tiny suturing locations in the recent devices (not shown here).
More importantly, the surface of ePTFE was investigated via SEM image analysis. Figure
48(c) shows a global view of the SEM image of the ePTFE outside. There are thrombosis
covered on some areas and ePTFE structure is shown beneath the thrombosis. Figure 48(d)
shows highly magnified SEM image, which explains individual blood products adhered on
the surface of ePTFE membrane. Aggregated platelets, fibrin networks, and accumulated
red blood cells were found in the thrombosis.
Figure 48: Gross look of the harvested device after the in vivo tests (a), (b), and SEM image
analysis of the thrombosis formed on ePTFE membrane (c), (d)
5.4 DISCUSSION
Stress-strain curve of ePTFE membranes in Figure 4 confirms that the ePTFE membrane
is less prone to be stretched in longitudinal direction compared with the stretchability in
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radial direction, i.e., ePTFE membrane exhibits anisotropic mechanical behaviors in terms
of tensile loading. This behavior can be explained from the microstructure of the ePTFE
fibers observed under SEM. As the ePTFE fiber networks show the two types of fibers, the
thick fiber struts (shown in blue circle in Figure 5(d)) and thin fibers connecting the fiber
struts (shown in red circle in Figure 5(d)). The ePTFE membrane is easier to be stretched
along the thin fiber directions and the fracture happens once the thin fibers are disconnected
from the thick fiber struts. Because of this unique stretch behavior in different directions,
the ePTFE tube shows anisotropic stress-strain behaviors under tensile loading. This unique
behavior of ePTFE membrane is beneficial for the customizable stent graft fabrication if the
device requires various diameters in one stent graft for the patients anatomy. Although the
porosity increases to around 14.40% under the applied strain of 200%, no blood leakage was
observed during the sweating test under 120 mmHg fluid pressure. The possible reason is
that the thin fibers in ePTFE membrane tend to overlap each other during the elongation
and thus reducing the pore size and creating the barriers for the blood flow to pass through.
For the mechanical behaviors of the nitinol backbone structure, there is a discrepancy
between the FEA results and experimental results in terms of radial force, which can be
attributed to the material property defined in FEA calculations and a simplified 3D model of
stent backbone during the stent crimping modeling. Specifically, an elastic material model
for the nitinol was assumed with the superelastic property simply ignored to reduce the
computation complexity during the analysis. Also the 3D stent backbone model imported
in Abaqus did not adopt a tapered design, both of which caused the deviations from the
measurement results. In the in vitro pullout force measurement, it is only an approximation
to the stent migration inside the vessels as the interactions between ePTFE grafts and vessel
tissues were not taken into account. Also, the blood vessel tissue is more flexible compared
to the silicone tubing used in the testing and the deployed stent will conform to the vessel
geometries. Regarding the limitations in mechanical behaviors of nitinol backbone structure,
the future work will include a more complete model with the defined superelastic material
properties for nitinol and a tapered design in 3D stent backbone model in Abaqus. In
the radial force analysis and measurement in vitro, the integration of ePTFE graft with the
nitinol backbone also needs to be considered to account for the effects of expansion in ePTFE
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graft. In the stent migration evaluations, the stent needs to be deployed in a more realistic
tissue model to mimic the more flexible blood vessel tissues.
5.5 SUMMARY AND CONCLUSIONS
A novel customizable stent graft was manufactured from a highly-stretchable ePTFE tube
and laser-welded nitinol backbone. Various in vitro study results including mechanical
behavior, porosity, sweating, and biocompatibility showed the highly-stretachable ePTFE
tubes ability for use in stent grafts. The stress-strain curve of ePTFE materials exhibited
anisotropic behaviors as the membrane can be stretched up to 550% in radial direction while
it showed negligible elongation in the longitudinal direction of the tube. The corresponding
micro-structured porosity increased from 3% to 24% during the strain loading up to 550% in
radial direction. Sweating test results showed that no leakage on the surface was observed
under the fluid pressure of 120 mmHg, which demonstrated its reliability as a stent graft
in the blood vessel. The early thrombogenic responses on ePTFE surface with 0%, 200%
and 400% stretchiness level demonstrated that longer exposure time to the non-heparinized
blood would lead to more blood cell adherence on the surface while the stretchiness level
has no significant impact. In addition, no significant amount of coagulation was observed on
the ePTFE surface with heparinized pig blood. The mechanical behaviors of nitinol stent
backbone in terms of radial force and stent migration were investigated both in finite element
analysis and in vitro. The radial force of the nitinol backbone when it was radially crimped
by 40% was approximately 2.98 N, and the pullout force with the 50% oversized stent was
measured as 2.65 N, which was sufficient for the stent graft. The prototype stent graft de-
signed for bleeding control was then fabricated based on the computational modeling results
using the integration process of the customized ePTFE and the laser-welded nitinol back-
bone. The venous size stent graft could be easily deployed and retrieved via a 9 Fr delivery
sheath. Angiography results demonstrated that the deployed stent graft in the swine model
showed successful bleeding control on the injured vessels. Gross look analysis showed the
pristine surface of the harvest devices except a few locations with local moderate thrombosis.
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The current study suggests that a highly-stretchable ePTFE tube is an excellent candidate
material for the next-generation customizable stent graft improving the clinical outcomes as
well as reducing the cost in device manufacturing.
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6.0 SUMMARIES AND TAKEAWAYS
In this dissertation, four types of innovative implantable medical devices have been devel-
oped and evaluated. Although the functionality and materials for these devices are various,
they share the same development process. A typical medical device, regardless of its func-
tionality and behaviors, always start with the concept generated from clinical needs. The
goal of developing novel implantable medical device is always to address the current unmet
clinical needs or improve the performance of current treatment. Then different materials
and structures need to be considered in terms of mechanical, biological and fluid behaviors
before prototyping. Once the materials and device structures are determined, the prototypes
can be fabricated using various manufacturing processes, such as traditional manufacturing
including machining and advanced techniques including microfabrication and 3D printing.
During the prototyping process, a few iterations in terms of CAD modeling, in vitro vali-
dations are always required to optimize the prototype devices. Finite element method is a
power method to evaluate the device structural, mechanical and fluid behaviors in a com-
plicated environment. Solidworks can be used to build the 3D model of prototype devices
and then transferred to finite element analysis software such as ANSYS and ABAQUS for
further analysis. The challenging issues in finite element analysis would be how to consider
the realistic conditions inside the human body. As vascular systems inside the human body
are highly complicated, it is critical to make assumptions to simplify our calculations dur-
ing the computational modeling. Some knowledges and experiences are also helpful to get
convergent solutions under complex boundary conditions and structures. Also the results
from computational modeling need to be validated using in vitro tests to justify its assump-
tions. Once the prototype design is optimized, it will undergo pre-clinical testings including
in vitro and in vivo evaluations. The testing system needs to be customized to meet the
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specific device requirements. During this stage, multiple testing systems and devices such
as mechanical tensile machines, load cells, pressure sensors and flow meters are available to
measure the corresponding physiological signals, but they should be assembled appropriately
as a whole testing system and should be able to mimic the human physiological conditions.
Finally it is also important to validate the device designs in animal models before clinical
testings and FDA approval.
My contributions of this dissertation include the 3D modeling and parameter optimiza-
tions in implantable medical device designs using finite element analysis software. Most of
the finite element methods are structural analysis and computational fluid dynamics based
on nitinol materials with superelastic properties. Also the customization of in vitro testing
instrument was also proposed to evaluate different prototypes in terms of material properties,
biocompatibility issues and structural behaviors.
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